Females of childbearing potential who are sexually active with a non sterilized male partner must use at least 1 highly effective method of contraception from the time of screening and must agree to continue using such precautions for 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy; non-sterilized male partners of a female patient must use male condom plus spermicide throughout this period; cessation of birth control after this point should be discussed with a responsible physician; not engaging in sexual activity for the total duration of the drug treatment and the drug washout period is an acceptable practice; however, periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control; female patients should also refrain from breastfeeding throughout this periodXx_NEWLINE_xXWomen of childbearing potential (?12 months of non-therapy-induced amenorrhea or surgically sterile) must have had a negative serum pregnancy test within the past 21 days and must use a birth control method in addition to barrier methods (condoms).Xx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive use two effective methods of birth control- including a medically accepted barrier method of contraceptive method (e.g., male or female condom) for the entire period in which they are receiving protocol therapy; abstinence is an acceptable method of birth controlXx_NEWLINE_xXAlthough they will not be considered formal eligibility (exclusion) criteria, physicians should recognize that the following may seriously increase the risk to the patient entering this protocol:\r\n* Psychiatric illness which would prevent the patient from giving informed consent\r\n* Medical condition such as uncontrolled infection (including human immunodeficiency virus [HIV]), uncontrolled diabetes mellitus or cardiac disease which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient\r\n* Patients with a “currently active” second malignancy other than non-melanoma skin cancers; patients are not considered to have a “currently active” malignancy if they have completed therapy and are free of disease for >= 3 years; there is an exception for patients with a history of well differentiated thyroid cancer that has progressed to anaplastic thyroid cancer\r\n* Patients who cannot swallow oral formulations of the agent(s)\r\n* Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study ; appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)\r\n* Efatutazone is metabolized by cytochrome P450, family 3, subfamily A, polypeptide 4/5 (CYP3A4/5), and inhibits CYP2C8, 2C9, 2C19, and 3A4, and is a substrate of P-glycoprotein (PgP) and breast cancer resistance protein (BCRP)Xx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control throughout protocol treatmentXx_NEWLINE_xXThe patient must agree to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agree to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drugXx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test and must agree to practice an effective means of birth controlXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use two methods of birth control- a medically accepted barrier method of contraceptive method (e.g., male or female condom) and a second effective method of birth control-during protocol therapy and for at least 4 months after the last dose of XL184; abstinence is an acceptable method of birth controlXx_NEWLINE_xXMen who are sterile OR agree to use at least two forms of a reliable and highly effective method of birth control and to not donate sperm and for at least 180 days following last dose of TRC105 or sorafenib.Xx_NEWLINE_xXFemale participants of childbearing potential must adhere to using a medically accepted method of birth control up to 28 days prior to screening and agree to continue its use during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use barrier methods of birth control while on study; WOCBP must agree to use effective contraception during treatment and for at least 5 months following the last dose of study treatmentXx_NEWLINE_xXWomen of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatmentXx_NEWLINE_xXFemales who are pregnant or lactating, fertile males, or females of child-bearing potential who are not willing to comply with an effective double method of birth control are NOT eligible for participationXx_NEWLINE_xXPatients who are pregnant or breast-feeding are not eligible; nursing mothers must agree not to breastfeed during therapy; females of childbearing potential must practice an effective method of birth control while participating in this study and for those who have achieved menarche, must have a negative pregnancy test prior to study entryXx_NEWLINE_xXSexually active male or female must be surgically sterile post-menopausal, or must agree to use a physician-approved method of birth control during the study through a minimum of 120 days after the last study drug administration.Xx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to starting treatment)Xx_NEWLINE_xXDue to unknown effects of this therapy on a fetus, pregnant women are excluded from this research. The male partner should use a condom. Females of child-bearing potential must be willing to utilize one of the more effective birth control methods during the study unless female has had a hysterectomy or tubal ligationXx_NEWLINE_xXFemale patients with negative pregnancy test at Screening and use of acceptable method of birth control for study duration, unless surgically sterile or postmenopausal for at least 1 year prior to Screening.Xx_NEWLINE_xXFemale patients who are not surgically sterile or postmenopausal (for at least 1 year) must practice at least one of the following methods of birth control throughout the duration of study participation and for at least 3 months after study treatment:Xx_NEWLINE_xXNon-vasectomized male patients must comply with at least one of the following methods of birth control throughout the duration of study participation and for at least 3 months after study treatment:Xx_NEWLINE_xXWomen who are pregnant or nursing. Female patients of childbearing potential must have a negative pregnancy test and must adhere to using a medically acceptable method of birth control prior to screening and agree to continue its use during the study and for 30 days after the last dose of study drug, or be surgically sterilized (e.g., hysterectomy or tubal ligation). Women of childbearing potential are defined as any female who has experienced menarche and who is NOT permanently sterile or postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause. Males must agree to use barrier methods of birth control while on study and for 90 days post last dose of study drug.Xx_NEWLINE_xXAdults of reproductive potential not employing two forms of birth control: \r\n* Males having partners who are female with child-bearing potential must agree that they and/or their partners will use at least two effective contraceptive methods (including one barrier method) when engaging in reproductive sexual activity throughout the study from the time of informed consent, and will avoid conceiving for 28 days after the last dose of CC-115Xx_NEWLINE_xXFertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug.Xx_NEWLINE_xXWomen of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatmentXx_NEWLINE_xXMales or females of reproductive potential may not participate unless they have agreed to use two effective contraceptive methods; abstinence in a non-sexually active child will be sufficient birth controlXx_NEWLINE_xXFertile men must agree to use an effective method of birth control during the study and for up to 3 months after the last dose of study drugXx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Females of childbearing potential must have a negative pregnancy test. It is not known if the antideacetylase activity of this experimental drug may be harmful to the developing fetus or nursing infant.Xx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus)Xx_NEWLINE_xXFemale subjects (if of child bearing potential) and male subjects (with a partner of child bearing potential) must use medically acceptable methods of birth control before study entry, for the duration of the study, and for at least 6 months after the last intake of study drug.Xx_NEWLINE_xXInclusion\n\n          1. Has provided written informed consent\n\n          2. Has advanced solid tumors (excluding breast cancer)\n\n          3. Has normal renal function, mild, moderate, or severe renal impairment and is not on\n             dialysis\n\n          4. ECOG performance status of ?2\n\n          5. Is able to take medications orally\n\n          6. Has adequate organ function\n\n          7. Women of childbearing potential must have a negative pregnancy test and must agree to\n             adequate birth control if conception is possible. Males must agree to adequate birth\n             control.\n\n        Exclusion\n\n          1. Certain serious illnesses or medical condition(s)\n\n          2. Has had certain other recent treatment e.g. major surgery, anticancer therapy,\n             extended field radiation, received investigational agent, within the specified time\n             frames prior to study drug administration\n\n          3. Has received TAS-102\n\n          4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any\n             prior therapies\n\n          5. Is a pregnant or lactating femaleXx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s)Xx_NEWLINE_xXMale patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administrationXx_NEWLINE_xXSexually active fertile men must use effective birth control if their partners are WOCBPXx_NEWLINE_xXMen and women of childbearing potential must be willing to practice an effective method of birth control during treatment and at least 4 months after treatment is finishedXx_NEWLINE_xXFemales of child-bearing potential and sexually-active males must consent to follow acceptable birth control methods to avoid contraception while on treatmentXx_NEWLINE_xXWomen who are pregnant or nursing a child may not take part in this study; subjects of childbearing ability must agree, with the study doctor, on a method of birth control to use throughout the study; subjects who think they have gotten pregnant during the study must notify the study doctor immediately; pregnant women will be taken out of the studyXx_NEWLINE_xXTREATMENT: Pregnant women are excluded from this research; the male partner should use a condom; females of child-bearing potential must be willing to utilize one of the more effective birth control methods during the study unless female has had a hysterectomy or tubal ligationXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001)Xx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control or practice abstinence during the study and for 4 months after the last dose of study drug(s)Xx_NEWLINE_xXWomen of childbearing potential who are sexually active and are not willing to use a highly effective method of birth control during the study periodXx_NEWLINE_xXMales who are sexually active and not willing to use a condom, and have a partner who is capable of becoming pregnant, if neither has had surgery to become sterilized, and/or who are not willing to use double barrier or whose partner is not using a highly effective method of birth controlXx_NEWLINE_xXMale subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study.Xx_NEWLINE_xXMale and female subjects of childbearing potential must agree to use an effective means of birth control to avoid pregnancy throughout the transplant procedure, while on immunosuppression, and if the subject experiences any chronic GvHDXx_NEWLINE_xXSexually active females of childbearing potential and males with partners of child bearing potential must agree to use birth controlXx_NEWLINE_xXWomen of childbearing potential are willing to agree to use 1 of the study-defined effective methods of birth control from the time of study entry to 6 months after the last day of treatmentXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the T cell infusionXx_NEWLINE_xXINCLUSION - TREATMENT: Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xX11. Females of childbearing potential must be willing to use an acceptable method of birth control (i.e., intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study.Xx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use two effective methods of birth control, including a medically accepted barrier or contraceptive method (e.g., male or female condom) for the duration of the study; abstinence is an acceptable method of birth controlXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.Xx_NEWLINE_xXPatients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 6 months after the last drug administrationXx_NEWLINE_xXIf fertile, willing to use effective birth control methods during the studyXx_NEWLINE_xXHighly effective forms of birth control include:Xx_NEWLINE_xXHighly effective forms of birth control include:Xx_NEWLINE_xXIf a female patient, must be surgically sterile, post-menopausal, or must agree to use physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administration, or if a male patient with a female partner, must agree to use physician-approved method of birth control during the study and for a minimum of 30 days after the last study drug administrationXx_NEWLINE_xXINCLUSION - INFUSION: Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXPatient on reliable birth control: combined oral contraceptive pill (OCP), long acting reversible contraceptive program (LARCP), bilateral tubal ligation (BLT) and Depo Provera shot/birth control shotXx_NEWLINE_xXPatient not on reliable birth controlXx_NEWLINE_xXMale patients with female partners of childbearing potential, and female patients of childbearing potential must agree to use effective birth control. Effective birth control and cessation of lactation must be complied at least 2 weeks prior to first study drug administration, during the trial participation, and for 3 months after the last dose of study drugXx_NEWLINE_xXTREATMENT INCLUSION: Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXWillingness to use 2 methods of birth control during the study and for 12 months after the last dose of ZW25Xx_NEWLINE_xXSexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of contraception during the course of the study and for 3 months after their last dose of study drug. Effective birth control includes:Xx_NEWLINE_xXFemale subjects must not be pregnant; willing to use 2 methods of birth control/abstinence if applicable through 120 days after the last dose of study drugXx_NEWLINE_xXPatients of reproductive potential must use an acceptable form of birth control or abstain from sexual activityXx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Female patients of childbearing potential must agree to use adequate contraceptive measures until 3 months after the last study drug is taken. Females of childbearing potential must have a negative pregnancy test. It is not known if the antideacetylase activity of this experimental drug may be harmful to the developing fetus or nursing infant.Xx_NEWLINE_xXFemale of childbearing potential, unless birth control used on study and 12 wks post-treatment.Xx_NEWLINE_xXMen and women of reproductive potential who are unwilling to practice a highly effective method(s) of birth control while on study through 1 week (women) or 12 weeks (men)Xx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the T cell infusion; male partner should use a condomXx_NEWLINE_xXFertile men or women unwilling to use effective forms of birth control or abstinence for one year after transplantationXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the ATL infusion; male partner should use a condomXx_NEWLINE_xXWomen of child bearing potential (WOCBP) must be willing to use medically acceptable methods of birth control during the study treatment and for one month after discontinuing study treatmentXx_NEWLINE_xXPHASE I: Sexually active male subjects must use an effective method of contraception (barrier method of birth control or abstinence) from the time of consent until at least 180 days following discontinuation of protocol therapyXx_NEWLINE_xXPHASE IB: Sexually active male subjects must use an effective method of contraception (barrier method of birth control or abstinence) from the time of consent until at least 180 days following discontinuation of protocol therapyXx_NEWLINE_xXPatients with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Contraception must be continued for at least 2 months following the last dose of poly-ICLC. Women of childbearing potential must have a negative pregnancy test. While animal reproductive studies have been negative, the simulated viral infection and anti-proliferative activity of this experimental drug may theoretically affect the developing fetus or nursing infant.Xx_NEWLINE_xXPregnant or breast-feeding females are excluded; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; abstinence is an acceptable method of birth controlXx_NEWLINE_xXPregnancy or lactation. Pregnancy is associated with considerable immune suppression and this additional parameter may interfere with the evaluation of dendritic cell induced immune responses in melanoma study subjects. Pregnancy test must be negative on all women of reproductive potential at baseline (within 7 days of entry into the study) and they must agree to use birth control measures while on the studyXx_NEWLINE_xXPatients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimenXx_NEWLINE_xXELIGIBILITY CRITERIA AT TIME OF TREATMENT: Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXPatients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control while being treated on this studyXx_NEWLINE_xXWomen of childbearing potential are willing to agree to use 1 of the study defined effective methods of birth control from the time of study entry to 6 months after the last day of treatmentXx_NEWLINE_xXPregnant women are excluded from this research; the male partner should use a condom; females of child-bearing potential must be willing to utilize one of the more effective birth control methods during the study unless female has had a hysterectomy or tubal ligationXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatmentXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes; (females of childbearing potential must have a negative serum pregnancy test within 7 days prior to administration of axitinib)Xx_NEWLINE_xXSubjects who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last study drug administrationXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; women of child bearing potential (WOCBP) or male study participants of reproductive potential must agree to use double barrier birth control method of contraception during the course of the study treatment period and for 3 months after completing study treatment; WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who are not postmenopausal (no menses) for at least 12 consecutive months; WOCBP must have a negative urine or serum pregnancy test within 7 days prior to administration of treatmentXx_NEWLINE_xXPatients in their reproductive age group should use an effective method of birth control; patients who are breast-feeding, or have a positive pregnancy test will be excluded from the studyXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXAll patients of childbearing potential must be willing to consent to using effective contraception, ie, intrauterine device, birth control pills, depo-provera, and condoms while on treatment and for 3 months after their participation in the study ends.Xx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXINCLUSION - TREATMENT: Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the cytotoxic T-lymphocyte (CTL) infusion; male partner should use a condomXx_NEWLINE_xXInability or refusal to practice effective contraception during therapy; men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for 4 months after completion of the treatmentXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXWilling to practice birth control during treatment and for four months after receiving the treatmentXx_NEWLINE_xXPatients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this studyXx_NEWLINE_xXWomen of child-bearing age and all men must use birth control of any type until at least 12 months after the last dose of therapyXx_NEWLINE_xXMen and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatmentXx_NEWLINE_xXFemales of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuationXx_NEWLINE_xXTREATMENT WITH SJCAR19: For females of child bearing age:\r\n* Not lactating with intent to breastfeed\r\n* Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\r\n* If sexually active, agreement to use birth control until 6 months after T-cell infusion; male partners should use a condomXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatment.Xx_NEWLINE_xXThe effects of enasidenib on the developing human fetus are unknown. For this reason women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during the entire study treatment period and through 6 months after the last dose of treatmentXx_NEWLINE_xXFemales of childbearing potential who are sexually active with a nonsterilized male partner agree to use 2 methods of effective contraception from screening, and agree to continue using such precautions for 90 days after the final dose of study drug; cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control.Xx_NEWLINE_xXMale patients must agree to use adequate birth control during the study and up to 30 days after the last avelumab doseXx_NEWLINE_xXPatient is a female of childbearing potential (FCBP)* with a negative serum or urine pregnancy test prior to initiation of therapy and agrees to practice appropriate methods of birth control, or the patient is male and agrees to practice appropriate methods of birth controlXx_NEWLINE_xXSubjects of childbearing potential must be willing to practice an approved highly effective method of birth control starting at the time of informed consent and for 1 year after the completion of the lymphodepletion regimen. Approved methods of birth control are as follows: hormonal contraception (i.e. birth control pills, injection, implant, transdermal patch, vaginal ring); intrauterine device (IUD); tubal ligation or hysterectomy; subject/partner status post vasectomy; Implantable or injectable contraceptives; and condoms plus spermicide.Xx_NEWLINE_xXPatients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimenXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for 1 month after the last dose of study drug; for males, these restrictions apply for 3 months after the last dose of study drugXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXCurrently pregnant, nursing, or planning to become pregnant during the study or within 1 month after study drug administration. Female subjects must be surgically sterile, at least 2 years menopausal, or using an acceptable method of birth control. If of childbearing potential, the subject must have a documented negative pregnancy test within 24 hours before surgery.Xx_NEWLINE_xXWilling to practice birth control during treatment and for four months after receiving the treatmentXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXMale patients whose sexual partners are WOCBP not using effective birth controlXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for sexually active women of childbearing potential, these restrictions apply for 5 months after the last dose of study drug; for sexually active men, these restrictions apply for 7 months after the last dose of study drugXx_NEWLINE_xXMales and females of reproductive potential who are not using and effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entryXx_NEWLINE_xXFemales of childbearing potential must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after treatment discontinuation. Subject's partner must also use barrier protection while subject is on study until 4 weeks after treatment discontinuation.Xx_NEWLINE_xXSubjects of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KTE-C19Xx_NEWLINE_xXWomen of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control, starting at Study Day 1 through at least 90 days after the last dose of study drug.Xx_NEWLINE_xXWomen of childbearing potential (WCBP) must agree to use highly effective methods of birth control throughout the duration of the study until 6 months following the last dose of study drug.Xx_NEWLINE_xXFemale patients of childbearing potential must have negative serum or urine pregnancy test within 72 hours of the first dose of MEK162; patient must not be pregnant or breast-feeding; patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 30 days following cessation of treatmentXx_NEWLINE_xXFemale subjects of childbearing potential must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment and 3 months after completionXx_NEWLINE_xXSexually active patients (men and women) must agree to use medically accepted barrier methods of contraception (e.g. male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used. All sexually active subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s).Xx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXPatients who are breastfeeding, pregnant or refuse to use an effective form of birth control are excluded; abstinence is considered an effective form of birth controlXx_NEWLINE_xXWomen of child-bearing potential must agree to utilize a form of birth control or agree to undergo sexual abstinence during radiation therapyXx_NEWLINE_xXNot willing to use an effective method of birth controlXx_NEWLINE_xXMale subjects who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and for up to 90 days after the last dose of GC4419 are excluded.Xx_NEWLINE_xXWomen of childbearing potential must use an acceptable form of birth control for 28 days prior to beginning study treatment, through the duration of study treatment, and for 3 months after discontinuing study treatmentXx_NEWLINE_xXWomen of childbearing capacity are required to have a negative serum pregnancy test before treatment and must agree to maintain highly effective contraception by practicing abstinence or by using at least two methods of birth control from the date of consent through the end of the study; if abstinence is not practiced, one of the two methods of birth control should be an oral contraceptive (e.g., oral contraceptive and a spermicide)Xx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; subjects should use adequate birth control for at least 3 months after the last administration of immune checkpoint inhibitorsXx_NEWLINE_xXMale patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administrationXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatmentXx_NEWLINE_xXPatients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this studyXx_NEWLINE_xXFertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug.Xx_NEWLINE_xXPregnant and breastfeeding women are excluded; women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 12 weeks after the study are excluded; this applies to any woman who has not experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months); male subjects must also agree to use effective contraception for the same period as aboveXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug.Xx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods as defined above. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception.Xx_NEWLINE_xXPatients who have partners of childbearing potential (e.g. female that has not been surgically sterilized or who are not amenorrheic for >= 12 months) must be willing to use a method of birth control in addition to adequate barrier protection as determined to be acceptable by the investigator during the study and for 13 weeks after last study drug administration. Please note that the efficacy of hormonal contraception may be decreased if administered with olaparib.Xx_NEWLINE_xXSexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatmentXx_NEWLINE_xXMale patients whose sexual partners are WOCBP not using effective birth controlXx_NEWLINE_xXOr, if of childbearing potential: Agree not to try to become pregnant during the study and for 28 days after the final study drug administration; and have a negative urine or serum pregnancy test at screening; and, if heterosexually active, agree to consistently use 2 forms of highly effective birth control (at least one of which must be a barrier method) starting at screening and throughout the study and for 28 days after the final study drug administration.Xx_NEWLINE_xXMale subject who is of childbearing potential and their female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (at least one of which must be a barrier method) starting at screening and continue throughout the study, and for 90 days after the final study drug administration.Xx_NEWLINE_xXAll sexually active subjects of reproductive potential must agree to use both a medically accepted barrier method (e.g., male or female condom) and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s);Xx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test at study entry; all sexually active patients will be educated regarding the teratogenic potential of the chemotherapy they receive, as well as the infectious risks of intercourse; contraceptive methods will be discussed and sexually active patients must agree to use an effective birth control method for the duration of the study; a medically acceptable method of contraception appropriate to the patient’s underlying disease, risk factors and lifestyle will be offered in consultation with gynecology or adolescent medicine and will commence on study entry; in general, most postmenarchal female patients may qualify to receive depot medroxyprogesterone acetate (DMPA) 150 mg intramuscularly (IM) or 104 mg/0.65 mL for subcutaneous (SC) injection; injection needs to be repeated every 3 months while on study; prior to IM injection, ensure that platelet count is > 30,000 x 10^9/L; patients ineligible or refusing injectable contraceptives will be offered other medically acceptable contraceptives if appropriate, such as oral contraceptives or birth control patch, or barrier methodsXx_NEWLINE_xXFemale patients who are pregnant or of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafter; serum or urine pregnancy test must be performed within 7 days of enrollmentXx_NEWLINE_xXMale patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.Xx_NEWLINE_xXWilling to follow strict birth control measuresXx_NEWLINE_xXif male (and whether or not surgically or medically sterile), agree to use during the study and for at least one month after the last dose of study drug a double barrier method of birth control (in addition to any other birth control method practiced by his partner) while engaging in sexual intercourse with a partner who is pregnant, possibly pregnant or able to become pregnant.Xx_NEWLINE_xXSubjects of reproductive potential who are not willing to employ effective birth control from screening to 1 year after last dose of vaccineXx_NEWLINE_xXMale and female subjects who agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence , or sterilized partner) and a barrier method (e.g., condoms, vaginal ring, sponge, etc) during the period of therapy; female patients of reproductive potential who are not surgically sterile must practice adequate birth control for a minimum of twelve months post-treatment; male patients who are not surgically sterile must practice adequate birth control for a minimum of three months post-treatmentXx_NEWLINE_xXPatients of childbearing potential must agree to use adequate birth control during and for 3 months after participation in this studyXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXTo avoid risk of drug exposure through the ejaculate (even men with vasectomies), subjects must use a condom during sexual activity while on study drug and for 3 months following the last dose of study drug. If the subject is engaged in sexual activity with a woman of childbearing potential, a condom is required along with another effective contraceptive method consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies and their partners. Donation of sperm is not allowed while on study drug and for 3 months following the last dose of study drug.Xx_NEWLINE_xXSubjects of reproductive potential who do not use effective methods of birth controlXx_NEWLINE_xXFemale subjects who are pregnant/breast-feeding or who are of reproductive potential and not employing acceptable methods of birth controlXx_NEWLINE_xXWomen of child bearing age must have pregnancy test at time of enrollment, agree to use of adequate contraception (birth control hormone or barrier method) for the duration of the study and for six months after discontinuation of systemic agentsXx_NEWLINE_xXNon-pregnant, non-breast-feeding women may be enrolled if they are willing to use 2 methods of birth control or are considered highly unlikely to conceive; highly unlikely to conceive is defined as 1) surgically sterilized, or 2) postmenopausal (a woman who is >= 45 years of age and has not had menses for greater than 1 year will be considered postmenopausal), or 3) not heterosexually active for the duration of the study; the two birth control methods can be either two barrier methods or a barrier method plus a hormonal method to prevent pregnancy; subjects should start using birth control from study day 1 throughout the study period up to 120 days after the last dose of study therapyXx_NEWLINE_xXMen and women of childbearing potential must practice birth control; women of child bearing potential must have a urine pregnancy test within 7 days of study entry; in accordance with topotecan hydrochloride (topotecan) administration guidelines, women must practice birth control for at least 1 month following chemotherapy infusion; men must practice birth control for at least four months following termination of chemotherapy infusionXx_NEWLINE_xXPatients of both genders must be willing to practice birth control during and for four months after receiving chemotherapyXx_NEWLINE_xXWilling to use appropriate birth control for patients of child-bearing potential;Xx_NEWLINE_xXSexually active male and female patients should use effective birth control (abstinence; hormonal or barrier method) for the duration of the study and at least 2 months from last dose.Xx_NEWLINE_xXMen and women of childbearing potential must be willing to exercise an effective form of birth control (abstinence/contraception) while on study and for 3 months after therapy completedXx_NEWLINE_xXPregnant or breastfeeding women will not be entered into this study due to risks of fetal and teratogenic adverse events as seen in animal studies. Pregnancy tests must be obtained in females who are post-menarchal and of child bearing potential (e.g. female that has not been amenorrheic for at least 12 consecutive months or surgically sterilized). Males or females of reproductive potential will not participate unless they have agreed to use effective contraception for the entire period in which they are receiving protocol therapy and for at least one month after treatment ends. Effective contraception is defined as intrauterine device (IUD), hormonal (birth control pill, injections, implants, patch), tubal ligation and partner’s vasectomy. Abstinence is an acceptable method of birth controlXx_NEWLINE_xXAll sexually active subjects of reproductive potential are required to use or start using a reliable method of birth control at least 2 weeks prior to study enrollment, throughout the study, and for at least 3 months following completion of study therapy.Xx_NEWLINE_xXNot pregnant, and if of childbearing potential, agrees to use adequate birth control (hormonal or barrier method of birth control or abstinence) prior to study entry and during the study and agrees not to donate sperm or ova, for the duration of the study and 12 months post implantation of the investigational device (refer to Section 7.3 Permissible and Prohibited Medications/Treatments)Xx_NEWLINE_xXA Woman of Childbearing Potential (WOCBP) practicing at least one protocol specified method of birth control starting at Study Day 1 through at least 180 days after the last dose of study drug.Xx_NEWLINE_xXAll participants who are able to have children must practice effective birth control while on study. Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study. If the participant is a female and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If the participant becomes pregnant during this study, she will be taken off this study. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctor.Xx_NEWLINE_xXSexually active fertile men not using effective birth control if their partners are of child bearing potentialXx_NEWLINE_xXMale patients and must be willing to practice birth control from the time of enrollment on this study and for four months following the final CAR T cell infusion; pre-menopausal patients (female patients who have had a menstrual period within the last year) must be willing to practice birth control from the time of enrollment and for one year following the final CAR T cell infusionXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial and for 8 weeks after stopping study drug, by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of EVE)Xx_NEWLINE_xXSubjects who are pregnant, breast-feeding or of reproductive potential who are not employing an effective method of birth control or are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time period.Xx_NEWLINE_xXSubjects of childbearing potential must agree to use hormonal or barrier birth control with spermicidal gel to avoid pregnancy during the studyXx_NEWLINE_xXPregnant females; breastfeeding females; and males and females of childbearing potential not willing to use two highly effective methods of birth control, one being barrier method. Intrauterine Devices (IUD) and birth control pills are not barrier methods, but are highly effective especially when combined with a barrier method (e.g. latex condom or a diaphragm or cervical cap) while taking investigational product (SY-1425) and continuing contraception use for at least 90 days after the last dose of study drug. Men/women should not donate sperm or ova during this time frame.Xx_NEWLINE_xXAnd, if heterosexually active, agree to consistently use 2 forms of highly effective birth control* (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 6 months after the final study drug administration.Xx_NEWLINE_xXMale subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception* consisting of 2 forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 6 months after the final study drug administrationXx_NEWLINE_xXMale subject must not donate sperm starting at Screening and throughout the study period and, for 6 months after the final study drug administration Note: *Highly effective forms of birth control include:Xx_NEWLINE_xXWomen of childbearing potential (WoCBP)* must agree to use acceptable non-hormonal contraceptive methods of birth control from the day of the screening pregnancy test and up to 3 months after the last intake of ODM-201.Xx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth controlXx_NEWLINE_xXWomen of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the study and until 12 months following the last study treatment.Xx_NEWLINE_xXFemales and males of childbearing potential must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 12 weeks (for males) and 5 months (for females) after treatment discontinuationXx_NEWLINE_xXSexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatmentXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active with a female partner of childbearing potential must be surgically sterilized, practicing abstinence, or agree to use 2 birth control methods before study entry, for the duration of study participation, and for 20 weeks after the final dose of study drug; cessation of birth control after this point should be discussed with a responsible physician. Women of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Two methods of contraception which are considered accurate per protocol must be combined. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth controlXx_NEWLINE_xXSexually active fertile men not using effective birth control if their partners are WOCBPXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) and men who are able to father a child, unwilling to be abstinent or use highly effective methods of birth control that result in a low failure rate of less than 1% per year when used consistently and correctly prior to study entry, for the duration of study participation and for at least 4 weeks after treatment has endedXx_NEWLINE_xXAgreement to exercise appropriate use of contraception. Subjects should use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at the time of screening for an enzalutamide study and continuing throughout the course of treatment and for at least three months after enzalutamide is discontinuedXx_NEWLINE_xXAgreement to exercise appropriate use of contraception; subjects should use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at the time of screening for an enzalutamide study and continuing throughout the course of treatment and for at least three months after enzalutamide is discontinuedXx_NEWLINE_xXFemale subjects who are pregnant, breast-feeding, or of reproductive potential who are not employing an effective method of birth control from screening to 180 days after the last dose of durvalumab + tremelimumab + olaparib combination therapy or 90 days after the last dose of durvalumab and olaparib therapy, whichever is the longer time periodXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; men should use adequate birth control for at least three months after the last administration of lenvatinibXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for 1 month after the last dose of study drug; for males, these restrictions apply for 3 months after the last dose of study drugXx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use two methods of birth control- a medically accepted barrier method of contraceptive method (e.g., male or female condom) and a second effective method of birth control- during protocol therapy and for at least 4 months after the last dose of cabozantinib; abstinence is an acceptable method of birth controlXx_NEWLINE_xXMale and female patients of reproductive potential must agree to follow accepted birth control measures throughout the study period and for 30 days after the last dose of either study drug for females and 3 months after the last dose of study drug for malesXx_NEWLINE_xXWomen of child-bearing potential (WOCBP) must be willing to use acceptable means of birth controlXx_NEWLINE_xXMen who could potentially father a child must also use birth controlXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study up to four months after treatment; patients must be willing to undergo testing for HPV-16 prior to becoming pregnant after this periodXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.Xx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXFor women of child bearing potential, documented negative pregnancy test within two weeks of study entry and agreement to acceptable birth control throughout the trial starting with the screening visit through 120 days after the last dose of study medication\r\n* Abstinence is an acceptable method of birth controlXx_NEWLINE_xXMale subjects with a female partner(s) of child-bearing potential must agree to use acceptable birth control throughout the trial starting with the screening visit through 120 days after the last dose of study medicationXx_NEWLINE_xXPregnant or breast-feeding females are excluded; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; abstinence is an acceptable method of birth controlXx_NEWLINE_xXWomen of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatmentXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXSubjects whose partners are women of childbearing potential (WOCBP) must use an adequate method of birth control while on study drug and at least for 3 weeks after discontinuation of study drug.Xx_NEWLINE_xXSubjects of reproductive potential must agree to use acceptable birth control methodsXx_NEWLINE_xXPatients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of chemoradiation (treatment) and for 3 months after discontinuing treatment; women of childbearing potential must have a negative serum or urine pregnancy test within 3 days prior to starting treatmentXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must practice 2 effective methods of birth control during the course of the study; male patients who are partners of WOCBP should also practice an effective method of contraception: postmenopausal women must be amenorrheic for >= 12 months to be considered of non-childbearing potential; women and men must continue birth control for the duration of the trial and >= 3 months after the last dose of study drug; all WOCBP MUST have a negative pregnancy test prior to first receiving study medication(s)Xx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after cells are no longer detected in the bloodXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months following the last dose of study drugXx_NEWLINE_xXFemales of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after treatment discontinuationXx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test within 7 days prior to the 1st dose, if more than 7 days prior, a urine pregnancy test must be performed before the 1st dose. The female subject must be willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last study IP administration. Highly effective methods of birth control include sexual abstinence, hormonal birth control, or intrauterine device (women), vasectomy or a condom with spermicide (men) in combination with barrier methods.Xx_NEWLINE_xXMale subjects who are willing to use highly effective methods of birth control during the period of therapy and for 6 months following the last IP administration.Xx_NEWLINE_xXAll study subjects must be willing to ensure that corresponding sexual partners practice these same methods of highly effective birth control for the same duration.Xx_NEWLINE_xXWomen and men of reproductive potential who are unwilling or unable to use an effective means of birth control during the study and for 3 months after receiving study drugXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for 12 months after last dose of obinutuzumab, or 1 month after the last dose of ibrutinib, whichever is later; for males, these restrictions apply for 12 months after the last dose of obinutuzumab or 3 months after the last dose of ibrutinib, whichever is laterXx_NEWLINE_xXMale patients whose sexual partners are WOCBP not using effective birth controlXx_NEWLINE_xXSexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatmentXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXEither a female or male of reproductive capacity wishing to participate in this study must be using, or agree to use, one or more types of birth control during the entire study and for 3 months after completing the study. Birth control methods may include condoms, diaphragms, birth control pills, spermicidal gels or foams, anti-gonadotropin injections, intrauterine devices (IUD), surgical sterilization, or subcutaneous implants. Another choice is for a subject's sexual partner to use one of these birth control methods. Women of reproductive capacity will be required to undergo a urine pregnancy test before completion of the post-screening informed consent process.Xx_NEWLINE_xXSubjects who are pregnant, breast feeding or sexually active and unwilling to use effective birth control while on treatment with TKIXx_NEWLINE_xXMale patients and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administrationXx_NEWLINE_xXUsing corticosteroids or estrogen-based oral birth controlXx_NEWLINE_xXPre-menopausal patients must have a negative pregnancy test and agree to use birth control methods while participating in the study; women of childbearing age and their male counterparts should use a barrier method of contraception during and for 3 months following protocol therapyXx_NEWLINE_xXPatients who are pregnant, breast-feeding, or unwilling to practice an effective method of birth controlXx_NEWLINE_xXFemales of child bearing potential and sexually active males must agree to use adequate birth control during study treatmentXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimenXx_NEWLINE_xXcommit to continued abstinence from heterosexual intercourse (excluding periodic abstinence or the withdrawal method) or begin two acceptable methods of birth control with a Pearl-Index ? 1%. without interruption from 4 weeks before starting study drug, throughout study drug therapy and for 12 months after end of study drug therapy, even if she has amenorrhoea. Apart from abstinence, acceptable methods of birth control are:Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) who are pregnant or lactating or unwilling to use 2 forms of effective birth controlXx_NEWLINE_xXMen who are fertile and sexually active unwilling to use 2 forms of effective birth control if their partners are WOCBPXx_NEWLINE_xXSubjects of reproductive potential must agree to use acceptable birth control methodsXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active with a woman of childbearing potential must be practicing a highly effective method of birth control during and after the study (12 months for women and 3 months for men), consistent with local regulations regarding the use of birth control methods for subjects participating in this clinical study; men must agree to not donate sperm during and for up to 3 months after their conclusion of therapy on studyXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception (simultaneous use of 2 methods of birth control) prior to study entry, for the duration of study participation and for 90 days following completion of therapy.Xx_NEWLINE_xXSubjects of reproductive potential must agree to use acceptable birth control methodsXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXSubjects of reproductive potential must agree to use acceptable birth control methodsXx_NEWLINE_xXNo pregnant or breastfeeding women; men or women of child bearing potential must agree to use an acceptable method of birth control (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for at least 90 days after last study treatment (radiation or fresolimumab); all women of child bearing potential (last menstrual period within the previous 12 months and not surgically sterile) will be tested for pregnancy at pre-entryXx_NEWLINE_xXSubjects of reproductive potential must agree to use acceptable birth control methodsXx_NEWLINE_xXWomen of child-bearing potential must have negative serum pregnancy test and use accepted highly effective methods of birth control throughout the study and for 90 days after dosing and must agree to use effective contraception.Xx_NEWLINE_xXFertile male subjects must agree to use a medically acceptable contraceptive method (allowed methods of birth control include vasectomy or condom with spermicide) during the trial and for a period of at least 6 months following the last administration of trial drugsXx_NEWLINE_xXWomen who are breast feeding, or have a positive pregnancy test (reproductive age should use effective birth control during study if randomized to SBRT treatment arm)Xx_NEWLINE_xXMen and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study; female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study; male subject agrees to use an acceptable method for contraception for the duration of the studyXx_NEWLINE_xXEffective birth control should be utilized as indicatedXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential OR agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXWOCBP and males with partners of child-bearing potential must agree to use adequate birth control throughout their participation and for 5 months following the last study treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test and must agree to use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administrationXx_NEWLINE_xXPatients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence during study treatment and 12 months after the last dose of alisertibXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test at study entry; all sexually active patients will be educated regarding the teratogenic potential of the chemotherapy they receive, as well as the infectious risks of intercourse; contraceptive methods will be discussed and sexually active patients must agree to use an effective birth control method for the duration of the study; a medically acceptable method of contraception appropriate to the patient’s underlying disease, risk factors and lifestyle will be offered in consultation with gynecology or adolescent medicine and will commence on study entry; in general, most postmenarchal female patients may qualify to receive depot medroxyprogesterone acetate (DMPA) 150 mg intramuscularly (IM) or 104 mg/0.65 mL for subcutaneous (SC) injection; injection needs to be repeated every 3 months while on study; prior to IM injection, ensure that platelet count is > 30,000 x 10^9/L; patients ineligible or refusing injectable contraceptives will be offered other medically acceptable contraceptives if appropriate, such as oral contraceptives or birth control patch, or barrier methodsXx_NEWLINE_xXFemale patients who are pregnant or breast-feeding or of reproductive potential not willing to use an effective method of birth control during study treatment and for at least 12 months thereafterXx_NEWLINE_xXWomen of child-bearing potential must be willing to practice an effective method of birth control while on treatmentXx_NEWLINE_xXPatients of both genders must practice birth control for four months after receiving the preparative regimen (lymphodepletion) and continue to practice birth control throughout the study; patients must have a documented negative pregnancy test (urine or serum) for women who have menstruated in the past 12 months and without sterilization surgeryXx_NEWLINE_xXMen and women of childbearing potential must be willing to practice an effective method of birth control during treatment and for at least 4 months following treatment on studyXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must affirm they are practicing a highly effective method of barrier birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during or after the study; these restrictions apply throughout the treatment period and for three months after the last dose of enzalutamideXx_NEWLINE_xXNot pregnant or lactating; sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXELIGIBILITY CRITERIA- LYMPHODEPLETION/INFUSION OF tvs-CTL: Patients must not be pregnant or lactating; sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXUse of an effective means of contraception (men and women) is mandated in subjects of child-bearing potential; female subjects will be advised that they not become pregnant for at least one month after completing participation in the study; avoiding sexual activity is the only certain method to prevent pregnancy; however, if subjects choose to be sexually active, they should use an appropriate “double barrier” method of birth control (such as female use of a diaphragm, intrauterine device [IUD], or contraceptive sponge, in addition to male use of a condom) or the use of prescribed “birth control” pills, injections, or implantsXx_NEWLINE_xXMen who are sexually active with WOCBP must use acceptable birth control methods; acceptable birth control methods include: oral or injectable hormonal birth control, intrauterine devices (IUDS), and double barrier methods (for example a condom in combination with spermicide); men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of investigational product; women who are not of childbearing potential (i.e., who are postmenopausal or surgically sterile) as well as azoospermic men do not require contraceptionXx_NEWLINE_xXMales must agree to use a medically acceptable form of birth control in order to be in this study and for 3 months after infusionXx_NEWLINE_xXAT THE TIME OF INFUSION: Sexually active subjects must be willing to utilize one of the more effective birth control methods for 6 months after the T cell infusion; the male partner should use a condomXx_NEWLINE_xXMen who are sterile (including vasectomy confirmed by post vasectomy semen analysis) or agree to use at least two forms of a reliable and highly effective method of birth control and to not donate sperm and for at least 180 days following last dose of TRC105, bevacizumab, paclitaxel, and/or carboplatinXx_NEWLINE_xXMen who are able to father a child must agree to use an acceptable method of birth control while receiving radiation, and for 3 months after radiationXx_NEWLINE_xXMen and women of child-bearing potential must agree to use effective birth control or abstinence during and for a period of 4 months after the last vaccination therapyXx_NEWLINE_xXTREATMENT: Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXPatients of childbearing potential must agree to use an effective birth control methodXx_NEWLINE_xXWomen of childbearing potential and men must agree to use a medically accepted form of birth control during the treatment and for 2 months following completion of study treatmentXx_NEWLINE_xXSexually active patients (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s)Xx_NEWLINE_xXTREATMENT: Pregnant women are excluded from this research; the male partner should use a condom; females of child-bearing potential must be willing to utilize one of the more effective birth control methods during the study unless female has had a hysterectomy or tubal ligationXx_NEWLINE_xXWomen who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control; double barrier contraceptives must be used through the trial by both sexes; oral, implantable, or injectable contraceptives are not considered effective for this studyXx_NEWLINE_xXFemales of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of effective contraception from screening, and must agree to continue using such precautions for 90 days after the final dose of investigational product; cessation of birth control after this point should be discussed with a responsible physician; periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control\r\n* Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause)\r\n* Subjects must use 2 acceptable methods of effective contraceptionXx_NEWLINE_xXWomen who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must affirm they are practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during or after the study; for females, these restrictions apply for 1 month after the last dose of study drug; for males, these restrictions apply for 3 months after the last dose of the study drugXx_NEWLINE_xXPregnant and breastfeeding women are excluded; women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period and up to 12 weeks after the study are excluded; this applies to any woman who has not experienced menarche and who has not undergone successful surgical sterilization or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months); male subjects must also agree to use effective contraception for the same period as aboveXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXWomen who are able to become pregnant and men who can father a child must use birth control while on study and for at least 8 weeks after your last dose of study drug(s); acceptable birth control includes a condom or a diaphragm with spermicidal jelly; and birth control methods that are taken by mouth, injected, or implanted; if you are already using birth control, you must check with the study staff to make sure that it is considered one of the acceptable forms to use in this studyXx_NEWLINE_xXWomen of childbearing potential and men who are not practicing an acceptable form of birth control (i.e. diaphragm, cervical cap, condom, surgical sterility or birth control pills. Women whose partner has or men who have undergone a vasectomy must use a second form of birth control).Xx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test (urine or serum) and must not be lactating at the time of informed consent\r\n* Women and men must use adequate birth control while taking part in this study (such as a condom or diaphragm with contraceptive cream/jelly, birth control pills, Norplant, abstinence [no sexual intercourse] or surgical sterilization)Xx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s)Xx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test within 14 days of treatment; patients must agree to use a reliable barrier method of birth control during and for 3 months following the last dose of study drugXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXSexually active fertile men not using effective birth control if their partners are women of child-bearing potential (WOCBP)Xx_NEWLINE_xXPatients of both genders must practice birth control for four months after receiving the preparative regimen (lymphodepletion) and continue to practice birth control throughout the study; patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery (Turnstile II)Xx_NEWLINE_xXPatients must not be pregnant or nursing. Women/men of reproductive potential must have agreed to use an effective contraceptive method (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.Xx_NEWLINE_xXPregnant and nursing women should be excluded from the protocol; if the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy; it is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this studyXx_NEWLINE_xXBe non-fertile or not pregnant or lactating & agree to use birth control during the study through the end of last treatment visitXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXNo patients who are pregnant or lactating will be allowed; patients of childbearing potential must practice an effective method of birth control while participating on this studyXx_NEWLINE_xXWomen of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study participation and for 2 months following completion of study treatmentXx_NEWLINE_xXMales and females must agree to use effective birth control methods during the course of vaccination (from the first vaccine to two weeks after the last vaccine)Xx_NEWLINE_xXFemale subjects of child-bearing potential must be using a medically accepted method of birth control before beginning study-drug treatment and agree to continue its use for 30 days after stopping study medication.Xx_NEWLINE_xXWomen of child-bearing potential must be willing to practice an effective method of birth control while on treatmentXx_NEWLINE_xXPatients of both genders must practice birth control for four months after receiving the preparative regimen (lymphodepletion) and continue to practice birth control throughout the study; patients must have a documented negative pregnancy test (urine or serum) for women who have menstruation in the past 12 months and without sterilization surgery (Turnstile II)Xx_NEWLINE_xXPatients who do not agree to practice appropriate birth control methods while on therapy.Xx_NEWLINE_xXMen and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study; female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study; male subject agrees to use an acceptable method for contraception for the duration of the studyXx_NEWLINE_xXIn agreement to use an effective barrier method of birth control to avoid pregnancy during the study and for a minimum of 30 days after study treatment, for all male and female patients who are fertileXx_NEWLINE_xXPregnant or breast-feeding female (women of childbearing potential [WOCBP], defined as not post-menopausal for 12 months or without previous surgical sterilization, must have a negative urine pregnancy test within 30 days of the first administration of domperidone and must either commit to continued abstinence from heterosexual intercourse or use an effective method of birth control during the course of the study)Xx_NEWLINE_xXPregnancy or lactation; patients must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry, for the duration of study participation and for 3 months after discontinuing therapyXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXPatients who are pregnant, breast feeding, or if sexually active and unwilling to use effective birth control for the duration of this study will be excludedXx_NEWLINE_xXFemales must not be pregnant or breast feeding, and must use accepted birth control methods; males must use accepted birth control methodsXx_NEWLINE_xXPregnant and/or breastfeeding women are excluded; women of child-bearing potential who are unwilling or unable to use and acceptable method of birth control to avoid pregnancy for the entire study period and up to 12 weeks after the study are excluded; male subjects must also agree to use effective contraception for the same period as aboveXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatmentXx_NEWLINE_xXWomen of child bearing potential must agree to use birth control for the duration of the studyXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; barrier contraceptives must be used throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of everolimus and sorafenib)Xx_NEWLINE_xXWomen of child-bearing potential must be willing to practice an effective method of birth control while on treatmentXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug; abstinence is an acceptable method of birth controlXx_NEWLINE_xXPatients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this studyXx_NEWLINE_xXEligibility criteria specific to the abemaciclib arm:\r\n* Participants must be willing and able to provide written informed consent/assent for the abemaciclib arm of the INSIGhT trial\r\n* Women of child bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from date of initial dose and for 3 months following the last dose of abemaciclibXx_NEWLINE_xXEligibility criteria specific to the neratinib arm:\r\n* Participants must be willing and able to provide written informed consent/assent for the neratinib arm of the INSIGhT trial\r\n* Women of child bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from date of initial dose and for 28 days following the last dose of neratinib; men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during intercourse with women of childbearing potential from date of initial dose and for 3 months following the last dose of neratinibXx_NEWLINE_xXThroughout study, male subject and a female partner who is of childbearing potential must use two acceptable methods of birth control (one of which must include a condom barrier method of contraception) starting at screening and continuing throughout the study period and for three months after the final study drug administration. Two acceptable methods of birth control thus include the following:Xx_NEWLINE_xXWomen of child-bearing potential who are sexually active with a non-sterilized male partner, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective contraception from screening throughout study treatment, and must agree to continue using such precautions for 6 months after the final dose of investigational product; cessation of birth control after this point should be discussed with a responsible physician. Highly effective methods include the following:Xx_NEWLINE_xXFemale subjects of childbearing potential and male subjects with partners of childbearing potential should ensure use of a highly effective method of birth control as defined in study protocolXx_NEWLINE_xXELIGIBILITY CRITERIA FOR REGISTRATION: women of child-bearing potential must agree to use an effective method of birth control on trial; an effective method of birth control includes surgical sterilization of woman or her partner, abstinence, or two barrier methods (e.g. condom plus diaphragm); or hormonal methods of birth control (oral contraceptives or intrauterine device)Xx_NEWLINE_xXFemales of childbearing age must be on an acceptable form of birth control per institutional standardsXx_NEWLINE_xXWomen of childbearing potential must agree to practice effective birth control throughout their participation in the treatment phase of the studyXx_NEWLINE_xXSubjects in their reproductive age group should use an effective method of birth control; subjects who are breast-feeding, or have a positive pregnancy test will be excluded from the studyXx_NEWLINE_xXIf a woman is of childbearing potential, a negative serum pregnancy test must be documented; women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) for duration of study treatment and for up to 4 weeks following the study treatmentXx_NEWLINE_xXPatients who are pregnant or breast-feeding are not eligible; nursing mothers must agree not to breastfeed during therapy; females of childbearing potential must practice an effective method of birth control while participating in this study and for those who have achieved menarche, must have a negative pregnancy test prior to study entryXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXAgree to use adequate birth control, if of childbearing potentialXx_NEWLINE_xXMen and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatmentXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the cytotoxic T lymphocyte (CTL) infusion; male partner should use a condomXx_NEWLINE_xXWomen of child-bearing potential and sexually active males must use an accepted and effective method of birth controlXx_NEWLINE_xXWomen who are pregnant (confirmed by a serum pregnancy test in females of reproductive potential) or breast-feeding; women of child-bearing potential and sexually active males must be advised to take precautions to prevent pregnancy during treatment (unless the subject or subject’s partner(s) is sterile (i.e. women who have had a hysterectomy or have been post-menopausal for at least twelve consecutive months) or remain abstinent, men and women of reproductive potential must agree to use TWO of the following forms of birth control every time they have sex throughout the study and for up to 3 months following discontinuation of study drug: condoms (male or female) with or without a spermicidal agent, diaphragm or cervical cap with spermicidal, intrauterine device (IUD), or surgical sterilization while participating in this study; hormonal birth control methods are not permittedXx_NEWLINE_xXWomen of child-bearing potential must use birth control (oral contraceptive, barrier, abstinence or any other acceptable method) for the duration of the studyXx_NEWLINE_xXPatients of both genders must practice birth control for four months after receiving the preparative regimen (Turnstile II - Chemotherapy/Cell Infusion - Inclusion Criteria)Xx_NEWLINE_xXif heterosexually active, agree to consistently use 1 form of highly effective birth control starting at Screening and throughout the study period and for 6 months after the final study drug administration.Xx_NEWLINE_xXMale subject has not had a vasectomy or is not sterile as defined below, subject's female partner(s) is utilizing 1 form of highly effective birth control*starting at Screening and continue throughout study treatment and for 6 months after the subject receives final study drug administrationXx_NEWLINE_xXParticipants of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) during treatmentXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test result before enrollment. Males and females of childbearing potential must agree to use a highly effective method of birth control during the study for at least 30 days after enrollment in the study.Xx_NEWLINE_xXSubjects of childbearing potential must agree to utilize effective contraceptive methods of birth control during study participation and for 30 days following the last treatment with IMP (Investigational Medicinal Product)Xx_NEWLINE_xXFemale participants / women of childbearing potential (WOCBP) must adhere to using a medically accepted method of birth control up to 28 days prior to screening and agree to continue its use during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use barrier methods of birth control while on study. WOCBP must agree to use effective contraception during treatment and for at least 5 months following the last dose of study treatment.Xx_NEWLINE_xXEither a female or male of reproductive capacity wishing to participate in this study must be using, or agree to use, one or more types of birth control during the entire study and for 3 months after completing the study. Birth control methods may include condoms, diaphragms, birth control pills, spermicidal gels or foams, anti-gonadotropin injections, intrauterine devices (IUD), surgical sterilization, or subcutaneous implants. Another choice is for a subject's sexual partner to use one of these birth control methods. Women of reproductive capacity will be required to undergo a urine pregnancy test before completion of the post-screening informed consent process.Xx_NEWLINE_xXWomen must not be able to become pregnant (e.g. post-menopausal for at least 1 year, surgically sterile, or practicing adequate birth control methods) for the duration of the study. Women of child bearing potential must have a negative serum or urine pregnancy test at the Screening Visit and be non-lactating. Both male and female patients of reproductive potential must agree to use a reliable method of birth control during the study.Xx_NEWLINE_xXWomen of child-bearing potential will practice a highly effective method of birth control during and for 3 months after the chemotherapy/ custirsen last dose. Men of reproductive potential who are not surgically sterile must agree to abstain from sexual activity or use medically accepted and highly effective method of contraception during and for 6 months after the chemotherapy/custirsen last dose.Xx_NEWLINE_xXWoman with child bearing potential must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIME, at least 4 weeks before she starts taking lenalidomideXx_NEWLINE_xXSubjects are required to agree to practice effective birth control (i.e. abstinence, intrauterine device for female subjects) during the study period.Xx_NEWLINE_xXFemale subjects of childbearing potential must have a negative serum pregnancy test at screening; subjects must agree to use a medically appropriate form of birth control from screening until 6 months after the last dose of study medicationXx_NEWLINE_xXWillingness of male and female subjects who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control from the first dose of study drug to 30 days after the last dose of duvelisib and for 12 months after last dose of ofatumumab. Sexually active men, and women using oral contraceptive pills, should also use barrier contraceptionXx_NEWLINE_xX218 Males and females of reproductive potential who are unwilling to practice highly effective method(s) of birth control while on study through 110 days (females) and 170 days (males) after receiving the last dose of study drug. Highly effective methods of birth control include sexual abstinence (males, females); vasectomy; bilateral tubal ligation/occlusion; or a condom with spermicide (males) in combination with hormonal birth control or intrauterine device (IUD) (females).Xx_NEWLINE_xXSexually abstinent or correct and consistent use of one of the following methods of birth control in addition to a male partner using a condom from Screening to 3 months after the last dose of study drug:Xx_NEWLINE_xXvasectomy in male partner. Male patients must agree to sexual abstinence or to consistently and correctly use a condom in combination with one of the above methods of birth control from Screening to 3 months after the last dose of study drug.Xx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Female of childbearing potential (less than 12 months post-menopausal) or male with a partner of childbearing potential either agrees to be abstinent or uses a medically acceptable form of birth control during the study and for a period of 1 year after if on Arm 1Xx_NEWLINE_xXHPV-ASSOCIATED OROPHARYNX SQUAMOUS CELL CARCINOMA: Female of childbearing potential (less than 12 months post-menopausal) or male with a partner of childbearing potential either agrees to be abstinent or uses a medically acceptable form of birth control during the study and for a period of 1 year after if on Arm 1Xx_NEWLINE_xXAll patients must practice a highly effective method of birth controlXx_NEWLINE_xXWomen of childbearing potential must use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry until 6 months after the infusion of IMA202 productXx_NEWLINE_xXAll participants who are able to have children must practice effective birth control while on study. Acceptable forms of birth control for female patients include: hormonal birth control, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence, for the length of the study. If the participant is a female and becomes pregnant or suspects pregnancy, she must immediately notify her doctor. If the participant becomes pregnant during this study, she will be taken off this study. Men who are able to have children must use effective birth control while on the study. If the male participant fathers a child or suspects that he has fathered a child while on the study, he must immediately notify his doctorXx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXRENAL & BLADDER: Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s)Xx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s)Xx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving the treatmentXx_NEWLINE_xXMen must be willing and able to use an acceptable method of birth control such as latex condom during the dosing period and for at least 3 months after completion of the study agent administration (T cell infusion and/or LV305 or CMB305) if their sexual partners are WOCBP.Xx_NEWLINE_xXMen must be willing and able to use an acceptable method of birth control, during and for at least 3 months after completion of the study, if their sexual partners are WOCBPXx_NEWLINE_xXMen (including men with vasectomies) must agree to use adequate contraception (a condom and another effective method of birth control) prior to registration, for the duration of study participation, and for at least 3 months thereafter; men must also agree not to donate sperm for the duration of study participation, and for at least 3 months thereafterXx_NEWLINE_xXMen and women of reproductive potential who are unwilling to practice acceptable methods of effective birth control while on study through 5 weeks (women) or 3 months (men) after receiving the last dose of AMG 232; acceptable methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or IUD (women)Xx_NEWLINE_xXMen or women of childbearing potential who are unwilling to employ adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment and for 4 months after the last dose of study therapyXx_NEWLINE_xXPatients who are pregnant, breastfeeding or plan to become pregnant; sexually active patients and their partners must be willing to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, during the study participation, and for four months after the last dose of T-VECXx_NEWLINE_xXWomen of child-bearing potential must agree to use an effective method of birth control during treatment and for 3 months after receiving their last dose of study drug; fertile men must also agree to use an acceptable method of birth control while on study drug and for at least 3 months after last doseXx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth controlXx_NEWLINE_xXPregnant, breastfeeding, or unwilling to practice birth control during participation in the studyXx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test (urine or serum) within 14 days prior to the start of the study drug treatment and must agree to use adequate birth control if conception is possible during the study and up to 6 months after discontinuation of study drug treatmentXx_NEWLINE_xXMale patients must agree to use adequate birth control during the study and up to 6 months after discontinuation of study drug treatmentXx_NEWLINE_xXPregnant women are excluded from this study; breastfeeding should be discontinued; women of child-bearing potential must agree to use adequate birth control throughout the study durationXx_NEWLINE_xXMales and females must agree, in the consent form, to use effective birth control methods during the course of vaccinationXx_NEWLINE_xXMale and female patients who do not agree to practice approved methods of birth control for the duration of the study are ineligibleXx_NEWLINE_xXPregnant and/or lactating women will be excluded; premenopausal patients will undergo pregnancy testing when indicated; women will practice effective birth control while receiving protocol treatmentXx_NEWLINE_xXIf of child-bearing potential, patient agrees to use adequate birth control measures during study participationXx_NEWLINE_xXSexually active women of childbearing age and men should be willing to use two acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing through 3 months after the final study drugs administration; men must agree to avoid sperm donation while on study and 3 months after the final study drugs administrationXx_NEWLINE_xXWomen who are pregnant or breast feeding, or women/men able to conceive and unwilling to practice an effective method of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing through 3 months after the final study drugs administrationXx_NEWLINE_xXPatients (men and women) of childbearing potential must agree to use double barrier method of birth control beginning at the signing of the informed consent form (ICF) until at least 3 months after the last dose of study drugXx_NEWLINE_xXSexually active fertile men not using effective birth control if their partners are WOCBPXx_NEWLINE_xXAll subjects, including those who are surgically sterilized, must be willing to use an effective method of contraception (barrier method of birth control or abstinence) from the time informed consent is signed until 6 months after completion of protocol therapyXx_NEWLINE_xXPatients who are pregnant or breast-feeding are not eligible for this study; negative pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective birth control methodXx_NEWLINE_xXAdequate birth controlXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of EVEROLIMUS)Xx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimenXx_NEWLINE_xXAdequate birth control in sexually active women of childbearing potentialXx_NEWLINE_xXAny women who are pregnant or breast feeding, or women/men able to conceive and unwilling to practice an effective method of birth controlXx_NEWLINE_xXFemale and male patients (and when relevant their partners) must be willing to practice birth control (including abstinence) during and for two months after treatment, if of childbearing potentialXx_NEWLINE_xXPregnancy or nursing or unwilling to take adequate birth control during therapy; NOTE: breastfeeding should be discontinuedXx_NEWLINE_xXFemales of childbearing potential who are sexually active with a non-sterilized male partner must use highly effective contraception from screening, and must agree to continue using such precautions for at least 90 days after the final dose of investigational product; cessation of birth control after this point should be discussed with a responsible physician; periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth controlXx_NEWLINE_xXMust agree to use effective birth control (such as a condom) or abstinence during and for a period of 6 months after the last vaccination therapyXx_NEWLINE_xXPatients of both genders must be willing to practice birth control during and for four months after receiving chemotherapyXx_NEWLINE_xXPatients must not be pregnant, lactating, or unwilling to use birth controlXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving the treatmentXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes; (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of study drug)Xx_NEWLINE_xXNon pregnant and non-nursing; treatment under this protocol would expose a fetus to significant risks; women of childbearing potential should have a negative pregnancy test prior to study entry; women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial; appropriate methods of birth control include oral contraceptives, implantable hormonal contraceptives (Norplant), or double barrier method (diaphragm plus condom)Xx_NEWLINE_xXFemale and male subjects must agree to use a medically acceptable method of birth control prior to screening and agree to continue its use throughout the study; females of childbearing potential should be counseled in the appropriate use of birth control while on this studyXx_NEWLINE_xXPatients of child-bearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four months after receiving the preparative regimenXx_NEWLINE_xXWomen of childbearing potential and fertile men who are not practicing or who are\n             unwilling to practice birth control while enrolled in the study until at least 12\n             weeks after the last milatuzumab infusionXx_NEWLINE_xXFemales of childbearing potential and males not using adequate birth control.Xx_NEWLINE_xXPatients must be able to rinse and expectorate study medication rather than swallow it; female patients must be willing to practice birth control (including abstinence) during and for two months after treatment, if of childbearing potentialXx_NEWLINE_xXWomen of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the studyXx_NEWLINE_xXPregnant and lactating women are excluded from this study; women of reproductive potential that are not using or are unwilling to use effective birth control methods throughout the trial are excludedXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion; male partner should use a condomXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXMen enrolled on this study should understand the risks to any sexual partner of childbearing potential and should practice an effective method of birth controlXx_NEWLINE_xXFemale patients of childbearing potential must use maximally effective birth control during the period of therapy, must be willing to use contraception for 1 month following the last study drug infusion and must have a negative urine or serum pregnancy test upon entry into this study. Otherwise, female patients must be postmenopausal (no menstrual period for a minimum of 12 months) or surgically sterile. 'Maximally effective birth control' means that the patient, if sexually active, should be using a combination of two methods of birth control that are approved and recognized to be effective by Regulatory AgenciesXx_NEWLINE_xXWomen of child-bearing potential (WOCP) and sexually active men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry, during treatment and for three months after completing treatmentXx_NEWLINE_xXThe participant, if male, is sterile or agrees to use a reliable method of birth control.Xx_NEWLINE_xXThe participant, if female, is surgically sterile, is postmenopausal, or agrees to use a highly effective method of birth control.Xx_NEWLINE_xXMust use acceptable form of birth control throughout the study. After the final dose of study drug, an acceptable form of birth control must be used for 23 weeks for women of childbearing potential (WOCBP) and 31 weeks for men who are sexually active with WOCBPXx_NEWLINE_xXSubject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting a Screening and continuing throughout the study period and for 3 months after final study drug administration • Two acceptable forms of birth control include:Xx_NEWLINE_xXFemales of child-bearing potential and males who use adequate birth control through 120 days post dose.Xx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; two acceptable forms of contraceptives must be continued throughout the trial by either sex; hormonal contraceptives are not acceptable as a sole method of contraception (women of childbearing potential must have a negative serum pregnancy test within 7 days prior to day 1 of study drug)Xx_NEWLINE_xXMales who cannot comply with birth control use to avoid fathering a childXx_NEWLINE_xXWomen of childbearing potential must commit to either abstain continuously from sexual intercourse or to use 2 methods of reliable birth control simultaneously as deemed appropriate by the Investigator. Contraception must begin 4 weeks prior to dosing and must continue for 3 months after the last dose of daratumumabXx_NEWLINE_xXFemale subject who is pregnant, breastfeeding, or if of child bearing potential is unwilling to practice birth control until 3 years following surgery.Xx_NEWLINE_xXPregnancy or nursing or unwilling to take adequate birth control during therapyXx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) at the time of the serum pregnancy test (women of childbearing potential only); during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s)Xx_NEWLINE_xXMen and women with reproductive potential: Must agree to use a reliable method of birth control during the study and for 3 months following the last dose of study drug(s) or country requirements, whichever is longer.Xx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.Xx_NEWLINE_xXIs pregnant or breast-feeding, since the effects of NPC-1C on the developing human fetus and nursing infants are unknown and potentially harmful, women of child-bearing potential must agree to use adequate contraception (hormonal or double barrier method of birth control or complete abstinence) prior to study entry, for the duration of study participation, and for three months after the last dose of investigational agent.Xx_NEWLINE_xXPatients of childbearing potential must agree to use an approved method of birth controlXx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth controlXx_NEWLINE_xXMale or female patients. Women of childbearing potential must agree to use highly effective methods of birth control during the trial and for at least 1 year after the last dose of BI 836826 and 1 month after the last dose of ibrutinib.Xx_NEWLINE_xXIf female of childbearing potential (FCBP), willing to undergo pregnancy testing and agrees to use two methods of birth control or is considered highly unlikely to conceive during the dosing period and for three months after last study treatment, or if receiving pembrolizumab, four months after last treatmentXx_NEWLINE_xXSubjects who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protections as determined acceptable by the principal investigator during the study and for 1 week after the last dose of abiraterone acetateXx_NEWLINE_xXBoth male and female patients of childbearing potential enrolled in this trial must use adequate birth control measures during the course of the trial and for at least one month after discontinuing study drug.Xx_NEWLINE_xXMales, and female patients who are biologically capable of having children, must agree to use a medically acceptable method of birth control.Xx_NEWLINE_xXOr, if of childbearing potential, Agree not to try to become pregnant during the study and for 180 days after the final study drug administration; And have a negative urine pregnancy test at Day 1; And, if heterosexually active, agree to consistently use two forms of highly effective birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 180 days after the final study drug administration.Xx_NEWLINE_xXMale subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 120 days after the final study drug administration.Xx_NEWLINE_xXWomen of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if ?55 years or 12 months if >55 years, must have a negative serum pregnancy test within four weeks prior to the first dose of study drug and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception are outlined in the protocol.Xx_NEWLINE_xXFemale patients of child bearing potential and non-vasectomized male patients agree to practice appropriate methods of birth controlXx_NEWLINE_xXFemale participants must be either surgically sterile (via hysterectomy or bilateral tubal ligation), post-menopausal, or agree to use a medically effective means of birth control (hormonal or barrier method of birth control; abstinence) prior to study entry and throughout their participation in the treatment phase of this study; female participants of child bearing potential must also have a negative serum pregnancy test within 2 weeks prior to registrationXx_NEWLINE_xXWomen who are pregnant or breast feeding. Adults of reproductive potential not employing two forms of birth control as per Pregnancy Prevention Risk Management Plan.Xx_NEWLINE_xXPregnant and/or breastfeeding or female patients of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXAll subjects, including those who are surgically sterilized, must be willing to use an effective method of contraception (barrier method of birth control or abstinence) from the time informed consent is signed until 6 months after completion of protocol therapy.Xx_NEWLINE_xXFertile male patients willing to use at least one medically acceptable form of birth control for the duration of the study and for 2 weeks after treatment stops.Xx_NEWLINE_xXA woman must agree to use an effective method of birth control and agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXAgree to use a reliable medically approved method of birth control.Xx_NEWLINE_xXFemale subjects and their male partners must agree must agree to use a highly reliable method of birth controlXx_NEWLINE_xXPatients (men and women) of child bearing potential should use an effective (for them) method of birth control throughout their participation in this studyXx_NEWLINE_xXWomen of childbearing potential must agree to use a medically acceptable form of birth control (medically accepted methods: birth control pills, condoms and spermicidal lubricants, intrauterine device, and diaphragm) during their participation in the studyXx_NEWLINE_xXPatients of childbearing potential must have a negative blood pregnancy test within 14 days of treatment; patients must agree to use a reliable barrier method of birth control during and for 3 months following the last dose of study drugXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; two acceptable forms of contraceptives must be continued throughout the trial by either sex and for 4 months (120 days) following last dose of either drug; hormonal contraceptives are not acceptable as a sole method of contraception; (women of childbearing potential must have a negative serum pregnancy test within 7 days prior to day 1 of study drug)Xx_NEWLINE_xXNon-child bearing potential or able to follow birth control requirementsXx_NEWLINE_xXWomen of childbearing potential must agree to use a medically acceptable form of birth control (medically accepted methods: birth control pills, condoms and spermicidal lubricants, intrauterine device, and diaphragm) during their participation in the studyXx_NEWLINE_xXSexually active fertile men not using effective birth control if their partners are WOCBPXx_NEWLINE_xXWomen of childl-bearing potential must have a negative pregnancy test within 7 days prior to starting the study drug. Beth males and females must agree to adequate birth control if conception is possible during the study and for 6 months after the last doseXx_NEWLINE_xXPatients with childbearing potential must agree to use appropriate forms of birth controlXx_NEWLINE_xXSexually active women and men of childbearing potential must agree to use an effective method of birth control during the course of the study and for up to 3 months following the last dose of the study drug, in a manner such that risk of pregnancy is minimized; surgical sterilization, intrauterine device, birth control pills, or barrier method (e.g. condom and/or diaphragm with spermicidal agents) are acceptable forms of birth control; women of childbearing potential must have a negative pregnancy test (serum) within 7 days prior to treatment; a pregnancy test is not required for registration; women who have not menstruated for more than 2 years will be considered postmenopausal, thus not of childbearing potentialXx_NEWLINE_xXMen and women of child bearing potential must agree to use adequate birth control throughout their participation in the study and for 30 days following the last study treatment.Xx_NEWLINE_xXWomen of child-bearing potential must have a negative pregnancy test within 7 days of initiation of dosing and must agree to use an acceptable method of birth control while on study drug and for 3 months after the last dose; women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for >=1 year; men who are able to father a child must also agree to use an acceptable method of birth control while on study drug, and for 3 months after the last doseXx_NEWLINE_xXFemale subject is either post-menopausal or surgically sterilized; females of childbearing potential must have a negative serum pregnancy test within 48 hours prior to prescribing bendamustine and must commit to continued abstinence from heterosexual intercourse or use TWO acceptable methods of birth control (at least one barrier method) AT THE SAME TIME during the study and for 6 months after the last study drug; sexually active males must use a medically acceptable form of birth control for the duration of the study and for 6 months after last dose of drugXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 3 months after the study is concluded; the male partner should use condomXx_NEWLINE_xXAll men and women of childbearing potential who are participating in the study must agree to use effective forms of birth control throughout the duration of their treatmentXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXFemale patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing; postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; male and female patients of reproductive potential must agree to employ an effective barrier method of birth control throughout the study and for up to 3 months following discontinuation of study drugXx_NEWLINE_xXSubjects must agree to consistently use 2 forms of highly effective contraception/birth control between signing of the informed consent and 60 days after the last study drug administration.Xx_NEWLINE_xXFemales of childbearing potential must agree to use highly effective forms of birth control throughout the course of the study and at least up to 90 days after last dose of study drug. Males must have undergone sterilization- vasectomy, or utilize a barrier methodXx_NEWLINE_xXMen and women of reproductive potential who are unwilling to practice acceptable methods of effective birth control while on study through 5 weeks (women) or 3 months (men) after receiving the last dose of AMG 232; acceptable methods of effective birth control include sexual abstinence (men, women); vasectomy; or a condom with spermicide (men) in combination with barrier methods, hormonal birth control or intrauterine device (IUD) (women)Xx_NEWLINE_xXSubjects of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KTE-C19Xx_NEWLINE_xXMale patients must be willing and able to use an acceptable method of birth control, during and for at least 3 months after completion of the study, if their sexual partners are WOCBP.Xx_NEWLINE_xXWomen of childbearing potential must agree to use highly effective methods of birth control.Xx_NEWLINE_xXWomen of childbearing potential (WOCBP) must practice 2 effective methods of birth control during the course of the study; male patients who are partners of WOCBP should also practice an effective method of contraception; effective methods of birth control include diaphragm or condoms with spermicidal foam or jelly, birth control pills (BCPs), injections or patches, intra-uterine devices (IUDs) and surgical sterilization; postmenopausal women must be amenorrheic for >= 12 months to be considered of non-childbearing potential, women and men must continue birth control for the duration of the trial and >= 3 months after the last dose of study drug, All WOCBP MUST have a negative pregnancy test prior to beginning ibrutinib on studyXx_NEWLINE_xXSubjects who are pregnant, breast-feeding or of reproductive potential who are not employing an effective method of birth controlXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trial; men must agree to not donate sperm during and after the study\r\n* For females, these restrictions apply for 1 month after the last dose of study drug; for males, these restrictions apply for 4 months after the last dose of study drugXx_NEWLINE_xXWomen of child-bearing potential are expected to use an effective method of birth control to prevent exposing a fetus to potentially dangerous agent with unknown riskXx_NEWLINE_xXFemale is not breastfeeding, is postmenopausal or surgically sterile; demonstrates non-pregnant state, and agrees to use 2 acceptable methods of birth control throughout the trial, until 120 days after the last dose of treatmentXx_NEWLINE_xXIf fertile male or female of child-bearing potential, agree to consistently use a highly effective method of birth control (including birth control pills, barrier device, or intrauterine device) from the time of consent through 4 months following the last dose of study drugXx_NEWLINE_xXContraception in patients with preserved reproductive capacity; patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy or bilateral tubal ligation/salpingectomy, or postmenopausal for at least two years; women of childbearing potential who are sexually active and not using a highly effective method of birth control during the trial and for at least three months (in case of monotherapy with BIBF 1120) after the end of active therapy are not allowed to participate in the trial; a highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs), sexual abstinence or vasectomized partnerXx_NEWLINE_xXMale and female patients of reproductive potential must agree follow accepted birth control measuresXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study; females of childbearing potential: must either completely abstain from heterosexual sexual conduct or must use 2 methods of reliable contraception, 1 highly effective (intrauterine device, birth control pills, hormonal patches, injections, vaginal rings, or implants) and at least 1 additional method (condom, diaphragm, cervical cap) of birth control; reliable contraceptive methods must be started at least 4 weeks before lenalidomide; males who are sexually active must be practicing complete abstinence or agree to a condom during sexual contact with a pregnant female or female of child bearing potential; men must agree to not donate sperm during and after the study; for females, these restrictions apply at least 4 weeks before study treatment, during the period of therapy and for 1 month after the last dose of study drug; for males, these restrictions apply during the period of therapy and for 3 months after the last dose of study drugXx_NEWLINE_xXOr, if of childbearing potential: must have a negative urine pregnancy test at Screening and on Day 1 before the first dose of study drug is administered, and must use 2 acceptable methods of birth control* if sexually active from Screening through 3 months after the last dose of study drug.Xx_NEWLINE_xXSexually active male subject and his female partner who is of childbearing potential must use 2 acceptable methods of birth control from Screening through 3 months after the last dose of study drug. * Two acceptable methods of birth control are as follows:Xx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for 4 months after the last dose of study drug(s)Xx_NEWLINE_xXInclusion Criteria:\n\n        Patients must meet the following criteria to be eligible for study participation:\n\n          1. Patients with recurrent squamous carcinoma of the Head and Neck, who in the opinion of\n             their treating physician, cannot be satisfactorily treated with surgery, radiation, or\n             platinum chemotherapy. Diagnosis must be confirmed by biopsy and histopathology.\n\n          2. Patient must have received prior systemic platinum-based chemotherapy for treatment of\n             their head and neck cancer, unless in the opinion of the medical oncologist, the use\n             of platinum-based chemotherapy is contraindicated or not recommended, e.g., renal\n             impairment, allergy to platinum compounds, age, liver disease, myelosuppression,\n             neuropathy, hearing loss, etc.\n\n          3. Patients must have life expectancy > 6 months based on investigator judgment.\n\n          4. Male or female patients at least 18 years old. Female patients must not be pregnant or\n             breast feeding and must be practicing a medically acceptable form of birth control, be\n             sterile, or post-menopausal. Females of childbearing potential (FCBP) is defined as\n             premenopausal women capable of becoming pregnant. This includes women who are\n             post-menopausal for at least 12 months after the last menses. FCBP must agree to use a\n             medically acceptable form of birth control during the study and for at least 6 months\n             after discontinuation of Erbitux® or study medication. Females must agree not to\n             breast feed during the study and for at least two months after discontinuation of\n             Erbitux® or study medication. Male patients should be using a double barrier\n             protection method that is a medically acceptable form of birth control during the\n             study or be sterile.\n\n          5. Patients must have an ECOG score of 0 - 2.\n\n          6. Patient must understand the investigational nature of this study and sign an\n             Independent Ethics Committee/Institutional Review Board approved written informed\n             consent form prior to receiving any study related procedure.\n\n        Exclusion Criteria:\n\n        Patients with any of the following will be excluded from participation in the study:\n\n          1. Patients with a history of significant Erbitux infusion reactions (? Grade 3).\n\n          2. Patients on chemotherapy or Erbitux® therapy or radiation therapy within 4 weeks of\n             enrollment.\n\n          3. Tumor invading a major blood vessel (such as the carotid artery) unless the vessel has\n             been embolized, stented or surgically ligated to prevent hemorrhage.\n\n          4. Tumor is not clearly shown on a CT scan or clinically measurable.\n\n          5. Location and extension of the tumor precludes an effective PIT.\n\n          6. Patients with impaired hepatic function (ALP (hepatic), AST and/or ALT >3 times the\n             upper normal limits, or total serum bilirubin > 2 mg/dL.\n\n          7. Patients with impairment of renal function (serum creatinine >2 mg/dL).\n\n          8. Unwilling or unable to follow protocol requirements.\n\n          9. Any condition which in the Investigator's opinion deems the patient an unsuitable\n             candidate to receive study drug.\n\n         10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements.\n\n         11. Patient requires examinations or treatments within 4 weeks after study drug\n             administration where they would be exposed to significant light, e.g., eye\n             examinations, surgical procedures, endoscopy, etc.Xx_NEWLINE_xXFemales of childbearing potential (FCBP) must have a negative serum or urine pregnancy test and must be willing to use acceptable methods of birth control during the study and for 90 days after the last dose of study treatment; acceptable methods of birth control include condoms with birth control foam, birth control pills, implantable or injectable birth control, birth control patch, intrauterine device (IUD), or diaphragm with spermicidal gel; male patients must use an effective barrier method of contraception (i.e. , condoms with birth control foam or diaphragm with spermicidal gel) during the study and for 90 days following the last dose of study treatment if sexually active with a female of childbearing potential; contraception must be in place at least 2 weeks prior to initiating study treatment; a female of childbearing potential is a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)Xx_NEWLINE_xXWilling to employ adequate and appropriate birth control if applicable\r\n* NOTE: This study is for patients aged 60 and older and most female patients will have entered menopause by this time; however patients should not become pregnant while on this study; pre-menopausal women need to use birth control while on this study and women should not breastfeed a baby while on this study; any man treated on this study will also need to use contraception if his partner is a premenopausal female; patients should check with their health care provider about what kind of birth control methods to use and how long to use themXx_NEWLINE_xXWomen of child-bearing potential and men must agree to adequate contraception (hormonal or barrier method of birth control; abstinence) during and up to 30 days after discontinuing treatmentXx_NEWLINE_xXWillingness to use acceptable birth control. Subjects with the potential for pregnancy or impregnating their partner must agree to follow acceptable birth control methods to avoid conception. Female subjects of child-bearing potential must have a negative pregnancy test.Xx_NEWLINE_xXPatients of childbearing potential must have a negative serum pregnancy test within 14 days of treatment; patients must agree to use a reliable method of birth control during and for 6 months following the last dose of study drugXx_NEWLINE_xXWomen of child-bearing potential must have a negative pregnancy test within 7 days of initiation of dosing and must agree to use an acceptable method of birth control while on study drug and for 3 months after the last dose; women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for >= 1 year; men of child-bearing potential must also agree to use an acceptable method of birth control while on study drug, and for 3 months after the last doseXx_NEWLINE_xXNote: Women with potential to have children must be willing to practice acceptable methods of birth control during the studyXx_NEWLINE_xXAll patients of childbearing potential must be willing to consent to using effective contraception, i.e., intrauterine device (IUD), birth control pills, Depo-Provera, and condoms while on treatment and for 3 months after their participation in the study endsXx_NEWLINE_xXWomen of childbearing potential and male participants must agree to use a medically effective means of birth control throughout their participation in the treatment phase of the studyXx_NEWLINE_xXWomen of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatmentXx_NEWLINE_xXWillingness to use effective means of birth control throughout the duration of clinical study and for at least 3 months after completion of study drugXx_NEWLINE_xXPatient agrees to use adequate contraception (barrier method of birth control) prior to study entry, during therapy and up to 3 months after last dose of ipilimumabXx_NEWLINE_xXAT THE TIME OF INFUSION: Sexually active patients must be willing to utilize one of the more effective birth control methods during the study and for 6 months after the study is concluded; the male partner should use a condomXx_NEWLINE_xXMale patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration; patients are also required to use a condom if having sex with a pregnant womanXx_NEWLINE_xXAdequate contraception must be used and patients must not be pregnant or breastfeeding; women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; men and women should use adequate birth control for at least thirty days after the last administration of sorafenibXx_NEWLINE_xXMen must be willing and able to use an acceptable method of birth control, for at least 3 months after completion of the study, if their sexual partners are WOCBPXx_NEWLINE_xXParticipants who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator (PI) during the treatment period and for 1 week after last dose of AAXx_NEWLINE_xXPatients who are breastfeeding, pregnant or refuse to use an effective form of birth control are excluded; abstinence is considered an effective form of birth controlXx_NEWLINE_xXWillingness of male and female subjects who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control from the first dose of study drug to 30 days after the last dose of duvelisib and for 12 months after last dose of ofatumumab. Sexually active men, and women using oral contraceptive pills, should also use barrier contraceptionXx_NEWLINE_xXMale subject and his female partner who is of childbearing potential must use two acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at Screening and continuing throughout the study period and for 3 months after final study drug administration.Xx_NEWLINE_xXTwo acceptable forms of birth control include:Xx_NEWLINE_xXFemales of childbearing potential who are sexually active with a nonsterilized male partner must use 2 methods of effective contraception from screening, and must agree to continue using such precautions for 6 months after the final dose of investigational product; cessation of birth control after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of birth control. Females of childbearing potential are defined as those who are not surgically sterile (i.e., bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause). Nonsterilized males who are sexually active with a female partner of childbearing potential must use 2 acceptable methods of effective contraception from Day 1 and for 6 months after receipt of the final dose of investigational product.Xx_NEWLINE_xXSubjects of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this studyXx_NEWLINE_xXPatients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator during the treatment period and for 1 week after last dose of abiraterone acetateXx_NEWLINE_xXmust use two forms of birth control* (at least one of which must be a barrier method) starting at Screening and throughout the study period and for 180 days after the final study drug administration. *Acceptable forms of birth control include:Xx_NEWLINE_xXMale subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control* (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 120 days after the final study drug administration.Xx_NEWLINE_xXWomen and men of childbearing potential must be willing to use an effective method of contraception (e.g. hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after protocol therapy discontinuation.Xx_NEWLINE_xXSexually active fertile men not using effective birth control if their partners are women of childbearing potential (WOCBP)Xx_NEWLINE_xXWillingness to use birth control while on studyXx_NEWLINE_xXFemales of childbearing potential and males able to father a child must be willing to practice acceptable methods of birth control to prevent pregnancyXx_NEWLINE_xXParticipants who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator during the treatment period and for 1 week after last dose of enzalutamideXx_NEWLINE_xXPatients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last dose of abiraterone acetateXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using barrier birth control methods, are not eligible for participationXx_NEWLINE_xXWillingness to discontinue sex hormonal therapy, e.g. birth control pills, prior to registration and while on studyXx_NEWLINE_xXWomen of child-bearing potential must have a negative pregnancy test within 14 days of initiation of dosing and must agree to use an acceptable method of birth control while on study drug and for 3 months after the last dose. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ?1 year. Men of child-bearing potential must also agree to use an acceptable method of birth control while on study drug, and for 3 months after the last dose.Xx_NEWLINE_xXPregnant or breast-feeding women will not be entered on this study; pregnancy tests must be obtained in girls who are post-menarchal; males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method during protocol therapy and for at least 30 days after the last dose of brentuximab vedotin; abstinence is an acceptable method of birth controlXx_NEWLINE_xXWomen of childbearing potential and sexually active males must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to enrollment and for the duration of study participation; protections against pregnancy must be continued for at least 8 months after the last dose of study drugXx_NEWLINE_xXPregnant women are excluded; we recommend that women of child-bearing potential use an acceptable method of birth control to avoid pregnancy for 6 months following stereotactic radiosurgery and that male subjects use effective contraception for the same periodXx_NEWLINE_xXPatients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator during the study and for 1 week after last dose of abiraterone acetateXx_NEWLINE_xXWomen of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) beginning 14 days prior to first dose of pazopanib, through the dosing period, and for at least 28 days after the last dose of pazopanibXx_NEWLINE_xXFemales of childbearing potential and males should agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participationXx_NEWLINE_xXMale patients whose sexual partners are WOCBP not using effective birth controlXx_NEWLINE_xXPregnancy or breastfeeding in women and women of childbearing potential not using an acceptable method of birth control.Xx_NEWLINE_xXWomen of child-bearing potential must be willing to practice an effective method of birth control while on treatmentXx_NEWLINE_xXSubjects of childbearing potential requires acceptable form of birth controlXx_NEWLINE_xXSexually active fertile men not using effective birth control if their partners are WOCBPXx_NEWLINE_xXWomen of child-bearing potential must agree to use an effective method of birth control during treatment and for six months after receiving their last dose of study drugXx_NEWLINE_xXSexually active participants (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all participants of reproductive potential must agree to use both a barrier method and a second method of birth controlXx_NEWLINE_xXInability or refusal to practice effective contraception during therapy or the presence of pregnancy or active breastfeeding (men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for 4 months after completion of treatment)Xx_NEWLINE_xXFemale patients of childbearing potential are not eligible unless they commit to complete abstinence or have been on 2 methods of birth control, including 1 highly effective method and 1 additional method at the same time (unless committing to complete abstinence of heterosexual intercourse) at least 28 days (4 weeks) prior to study enrollment; sexually active females must also agree to remain on 2 methods of birth control, during treatment (including during dose interruptions), and continuing for at least 28 days after the completion of protocol therapy; examples of methods of contraception are as follows:\r\n* Highly effective methods (must use at least 1):\r\n** Intrauterine device (IUD)\r\n** Hormonal (prescription birth control pills, injections, implants)\r\n** Tubal ligation\r\n** Partner’s vasectomy\r\n* Additional effective methods:\r\n** Male condom\r\n** Diaphragm\r\n** Cervical cap\r\nThe two methods of birth control requirement applies to all sexually active females unless they have undergone a hysterectomy or bilateral oophorectomyXx_NEWLINE_xXPregnant women and women of child-bearing potential who are not using an effective method of birth controlXx_NEWLINE_xXNon-pregnant and non-nursing; women and men of reproductive potential should agree to use an effective means of birth controlXx_NEWLINE_xXFemales who are pregnant or breast-feeding during the study period will be excluded; adults of reproductive potential not employing an effective method of birth control will be excluded; sexually active women of child bearing potential, whose partner is male, must use medically accepted birth control; sexually active men, whose partner is a female of childbearing potential, must use a medically accepted birth controlXx_NEWLINE_xXWomen of childbearing potential must agree to use adequate birth control measures and agree to not donate eggs for the purpose of assisted reproduction during the study and for 3 months after receiving the last dose of study agent, and must have a negative pregnancy test at screeningXx_NEWLINE_xXMen must agree to use a double-barrier method of birth control and to not donate sperm during the study and for 3 months after receiving the last dose of study agentXx_NEWLINE_xXFemales of child-bearing potential and sexually-active males must consent to follow acceptable birth control methods to avoid contraception while on treatmentXx_NEWLINE_xXSubjects of reproductive potential agree to use birth control throughout their participation in this study, and for three months following study termination.Xx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving the treatmentXx_NEWLINE_xXSexually active subjects must agree to use medically accepted methods of birth control during the course of the study and for 3 months following discontinuation of study treatments (excluding women who are not of child bearing potential and men who have been sterilized)Xx_NEWLINE_xXMen and women of child-bearing potential must be willing to practice an effective method of birth control during treatment and at least 4 months after treatment is finishedXx_NEWLINE_xXMen and women with reproductive potential must agree to use an acceptable method of birth control during treatment and for six months after completion of treatmentXx_NEWLINE_xXFemale subjects of child-bearing potential and male subjects with partners of child-bearing potential must agree to use an effective means of birth control while on study therapy and for a minimum of 4 months following last plerixafor dose and 6 months following last bevacizumab dose\r\n* Effective birth control includes:\r\n** Birth control pills, depot progesterone, or an intrauterine device plus one barrier method\r\n** or 2 barrier methods\r\n* Effective barrier methods are male and female condoms, diaphragms, and spermicides (creams or gels that contain a chemical to kill sperm)\r\n* Hormonal contraceptive methods are not sufficient, as information about any interaction of plerixafor with hormonal contraceptives is not known\r\n* Men or women of child-bearing potential (WOCP) who are unwilling or unable to use an acceptable method to avoid pregnancy (noted above) for the entire study period and for up to 2 weeks after the last dose of study drug are excluded from this studyXx_NEWLINE_xXPregnant or breast feeding women, or women of child-bearing potential (and/or their partners) who are unwilling to utilize an approved method of birth control during the study and for 1 month afterwardXx_NEWLINE_xXPatients of childbearing potential (females who have not been postmenopausal for at least 12 consecutive months or who have not undergone previous surgical sterilization or males who have not been surgically sterilized) must be willing to practice birth control during the studyXx_NEWLINE_xXWomen of childbearing potential and men with reproductive potential must be willing to continue practicing acceptable methods of birth control during the study NOTE: Oral contraceptives are not reliable due to potential drug-drug interaction with GSK2118436Xx_NEWLINE_xXPatients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this studyXx_NEWLINE_xXWomen of childbearing potential must have a negative serum beta-human chorionic gonadotropin (HCG) within 72 hours prior to study entry and must be willing to practice effective birth control to prevent pregnancy while receiving treatment and for three months after treatment is discontinued; all males of child fathering potential must also be willing to practice effective birth controlXx_NEWLINE_xXFemale subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control .Xx_NEWLINE_xXNon-pregnant and non-nursing; women and men of reproductive potential should agree to use an effective means of birth controlXx_NEWLINE_xXPatients who are pregnant or breastfeeding or patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of durvalumab + tremelimumab combination therapy or 90 days after the last dose of durvalumab monotherapy, whichever is the longer time periodXx_NEWLINE_xXA man who is sexually active with a woman of childbearing potential must agree to use a barrier method of birth control during the study and for 4 weeks after receiving the last dose of study drug. All men must also not donate sperm during the study and for 90 days after receiving the last dose of study drug.Xx_NEWLINE_xXWomen of childbearing potential (WOCP) must have a negative pregnancy test result prior to enrollment. WOCP and men whose partners are WOCP must agree to use a highly effective method of birth control during the study and for 6 months following the last dose of study drug. A highly effective method of birth control is defined as one which results in a low failure rate (less than 1% per year).Xx_NEWLINE_xXconsistent and correct use of 1 of the following highly effective methods of birth control for one month prior to the start of the study agent and 6 months after the last dose:Xx_NEWLINE_xXPatients (men and women) of childbearing potential must use effective method of birth control throughout their participation in this studyXx_NEWLINE_xXPatients must not be pregnant; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatmentXx_NEWLINE_xXNon-pregnant and non-nursing; women of child bearing potential and men must agree to use an appropriate method of birth control throughout their participation in this study; appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives (Norplant), or double barrier methods (diaphragm plus condom)Xx_NEWLINE_xXWomen of childbearing potential and men must agree to use a medically accepted form of birth control for the duration of study participation and for 4 months following completion of study treatmentXx_NEWLINE_xXPregnant and lactating women will be excluded; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatmentXx_NEWLINE_xXThe effects of dendritic cell vaccines on the developing human fetus are unknown; for this reason men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participationXx_NEWLINE_xXPatients of both gender must practice a barrier method of birth control while participating in this trialXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for four months after treatmentXx_NEWLINE_xXStudy participant must use birth control measure prior to study entry (during screening), during study participation, and for 12 weeks after bevacizumab is discontinuedXx_NEWLINE_xXSexually active fertile men not using effective birth control if their partners are WOCBPXx_NEWLINE_xXSexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion; the male partner should use a condomXx_NEWLINE_xXFemales who are pregnant or need to breast feed during the study period will be excluded; patients found to be pregnant will be excluded; male and female enrolled patients will be advised to practice an effective method of birth controlXx_NEWLINE_xXFemale patients of childbearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing; postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential; surgical sterilization is considered non-childbearing potential; female patients of reproductive potential must agree to employ an effective method of birth control (hormonal or barrier) throughout the study and for up to 3 months following discontinuation of study drugXx_NEWLINE_xXOr, if of childbearing potential: Agree not to try to become pregnant during the study and for 28 days after the final study drug administration; And have a negative serum pregnancy test at Screening; And, if heterosexually active, agree to consistently use 2 forms of highly effective birth control (at least 1 of which must be a highly effective method and one must be a barrier method) starting at Screening and throughout the study period and for 28 days after the final study drug administration.Xx_NEWLINE_xXMale subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.Xx_NEWLINE_xXFor males and females of child-bearing potential, willingness to use adequate birth control through 90 days after the last dose of epacadostat or atezolizumab.Xx_NEWLINE_xXWomen of childbearing potential who are not using an acceptable method of birth control (e.g., pill, patch, IUD, ring, condom, sponge, foam).Xx_NEWLINE_xXWomen of child-bearing potential must have a negative pregnancy test within 7 days of initiation of dosing and must agree to use an acceptable method of birth control. Women of non-childbearing potential may be included if they are either surgically sterile or have been postmenopausal for ?1 year. Fertile men must also agree to use an acceptable method of birth control while on study drug and up to 3 months after the last dose of study drug.Xx_NEWLINE_xXSubjects and spouse/partner who are of childbearing potential must be using high effective contraception consisting of 2 forms of birth control (at least 1 of which much be barrier method) starting at Screening and continuing through the entire study (for at least 3 months after the last dose of ALXN1007 if study treatment is stopped early or subject withdraws consent).Xx_NEWLINE_xXSubjects who are pregnant, breast feeding or sexually active and unwilling to use effective birth control for the duration of the study.Xx_NEWLINE_xXWomen of childbearing potential must agree to practice effective birth control throughout their participation in the treatment phase of the studyXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must affirm they are practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during or after the study; for females, these restrictions apply for 1 month after the last dose of study drug; for males, these restrictions apply for 3 months after the last dose of the study drugXx_NEWLINE_xXWoman of potential childbearing age agrees to a medically effective birth control method,Xx_NEWLINE_xXMen and women of child bearing potential must agree to use adequate birth control throughout their participation in the study and for 60 days following the last study treatment.Xx_NEWLINE_xXAnd if heterosexually active, agrees to consistently use 1 form of highly effective birth control* starting at screening and throughout the study period and for 28 days after the final study drug administration.Xx_NEWLINE_xXHighly effective forms of birth control include:Xx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for women, these restrictions apply for 1 month after the last dose of study drug; for men, these restrictions apply for 3 months after the last dose of study drugXx_NEWLINE_xXThroughout the study, male patients and their female partners of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration. Two acceptable methods of birth control thus include the following:Xx_NEWLINE_xXWomen of child-bearing potential must have a negative pregnancy test within 7 days prior to initiation of dosing and must agree to use an acceptable method of birth control from the time of the negative pregnancy test up to 3 months after the last dose of study drug, Fertile men must also agree to use an acceptable method of birth control while on study drug and up to 3 months after the last dose of study drug.Xx_NEWLINE_xXFemales must be post-menopausal for more than 2 years or surgically sterile or practicing acceptable forms of birth control.Xx_NEWLINE_xXAnd, if heterosexually active, agree to consistently use 2 forms of highly effective birth controlXx_NEWLINE_xXMale subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of 2 forms of birth controlXx_NEWLINE_xXFor female subjects of childbearing potential, the subject presents with a negative serum pregnancy test at screening and agrees to employ 2 forms of adequate birth control measures, including at least 1 barrier method (eg, diaphragm with spermicidal jelly or foam, or [for male partner] condom) throughout the course of the study and for at least 90 days after the last administration of BAX69. Other acceptable contraceptive measures include birth control pills/patches or intrauterine devicesXx_NEWLINE_xXThroughout study, male subject and a female partner who is of childbearing potential must use 2 acceptable methods of birth control (1 of which must include a condom barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administration. Two acceptable methods of birth control thus include the following:Xx_NEWLINE_xXThe patient is pregnant or unwilling to practice appropriate birth controlXx_NEWLINE_xXAdequate birth control in fertile patientsXx_NEWLINE_xXAll subjects of childbearing potential must agree to use acceptable methods of birth control (men and women)Xx_NEWLINE_xXAdequate birth control when appropriateXx_NEWLINE_xXSubjects who are fertile agree to use an effective barrier method of birth control (ie, latex condom, diaphragm, cervical cap, etc) to avoid pregnancy. Female subjects need a negative serum or urine pregnancy test within 7 days of study enrollment (applies only if subject is of childbearing potential. Non?childbearing is defined as ? 1 year postmenopausal or surgically sterilized).Xx_NEWLINE_xXIn agreement to use an effective barrier method of birth control to avoid pregnancy during the study and for a minimum of 30 days after study treatment, for all male and female patients who are fertileXx_NEWLINE_xXFemale subjects of childbearing potential and male subjects with partners of childbearing potential should ensure use of a highly effective method of birth control as defined by the investigator, for example, those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly during the study and for a period of 3 months following the last dose of any drug administered during the study.Xx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXFertile male subjects willing to use at least one medically acceptable form of birth control for the duration of the study and for 2 weeks after treatment stopsXx_NEWLINE_xXNon-menopausal or non-sterile female subjects of childbearing potential must have a negative serum beta-HCG and use a medically acceptable form of birth controlXx_NEWLINE_xXAny risk of pregnancy - ALL female patients must have an effective means of birth control or be infertile due to hysterectomy, fallopian tube surgery, or menopauseXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXNot pregnant, not lactating, and agree to use effective birth controlXx_NEWLINE_xXFCBP must agree to use a highly-effective form of birth control while taking the study drug and for 1 month after the last dose of study drug; highly-effective forms of birth control include implants, injectables, birth control pills with 2 hormones, some intrauterine devices (IUDs), or having a sterilized partner; the type of birth control used must be discussed with and approved by the attending physician prior to initiation of study drugXx_NEWLINE_xXFemale subjects of childbearing potential must have negative pregnancy test within 7 days prior to first dose of study drug; practicing an acceptable form of birth control for greater than 2 months prior to screening and commits to use for the duration of the study and for 3 months following the last dose of study treatment.Xx_NEWLINE_xXMale subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 3 months after the last dose of study treatment in such a manner that the risk of pregnancy for a partner is minimized.Xx_NEWLINE_xXPregnant and breastfeeding women are excluded; as well as women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the duration of the studyXx_NEWLINE_xXFemale patients (and when relevant their male partners) must be willing to practice birth control (including abstinence) during and for two months after treatment, if of childbearing potentialXx_NEWLINE_xX15. Men and women of childbearing potential must agree to use adequate contraception(double barrier birth control) for the duration of study therapy and for 3 months after the last dose of VS-6063.Xx_NEWLINE_xXWomen who are pregnant or lactating, as well as women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the duration of the studyXx_NEWLINE_xXPregnant or breastfeeding women and adults of reproductive potential not employing an effective method of birth control are excluded from this studyXx_NEWLINE_xXSexually active subjects and their partners must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the studyXx_NEWLINE_xXTREATMENT: Patients must be willing to practice birth control during and for four months following treatmentXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after the last dose of panobinostatXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after the last dose of panobinostatXx_NEWLINE_xXWomen of child-bearing potential must agree to use adequate contraception (barrier method of birth control; abstinence); women must not breast feed while on studyXx_NEWLINE_xXFor patients of childbearing potential, agreement to use two effective forms of contraception (e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) and to continue its use for the duration of the study and for 30 days after the last LY3023414 doseXx_NEWLINE_xXWomen of reproductive potential must be non-pregnant and non-nursing and must agree to employ an effective barrier method of birth control throughout the study and for up to 6 months following treatmentXx_NEWLINE_xXFertile men must agree to use an effective method of birth control during the study and for up to 6 months after the last dose of study drug.Xx_NEWLINE_xXMale patients whose sexual partners are WOCBP not using effective birth controlXx_NEWLINE_xXThe patient, if female and of child bearing potential, must be postmenopausal or surgically sterile, or on one of the following methods of birth control for a minimum of 2 months prior to entry into this study and throughout the duration of the study: intrauterine device (IUD), oral contraceptives, or Depo-Provera; this criteria can be waved at the discretion of the investigator if the patient’s intracranial tumor is considered life threatening and the 2 month wait required is not in the best interest of the patient; in this case, the patient must be on a reliable form of birth control as stated aboveXx_NEWLINE_xXMen and women of reproductive potential must agree to follow accepted birth control methods for the duration of the study. Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test at screening and must agree to use a highly effective birth control method from the time of the first dose of study drug through 45 days after last dose of study drug.Xx_NEWLINE_xXWilling to use physician approved birth control methodXx_NEWLINE_xXPatients who are known or thought to be sexually active must use effective birth control.**Xx_NEWLINE_xXEffective birth control includes absolute abstinence, or double barrier birth control methods, i.e. condom and one of the following: combined oral contraceptive, diaphragm, depot contraceptive injection.Xx_NEWLINE_xXWomen of child-bearing potential must agree to use an effective method of birth control during treatment and for three months after receiving their last dose of study drug. Fertile men must also agree to use an acceptable method of birth control while on study drug and for at least 3 months after last dose.Xx_NEWLINE_xXWomen of child-bearing potential must either commit to continued abstinence from heterosexual intercourse or begin one acceptable method of birth control (IUD, tubal ligation, or partner's vasectomy) while on crenolanib and for 3 months following the last dose of crenolanib. Hormonal contraception alone is not an acceptable method of birth control for the purpose of this trial.Xx_NEWLINE_xXA woman must be either: Not of childbearing potential: postmenopausal (more than [>] 45 years of age with amenorrhea for at least 12 months; If, of childbearing potential must be practicing a highly effective method of birth controlXx_NEWLINE_xXOr, if of childbearing potential: agree not to try to become pregnant during the study and for 60 days after the final study drug administration and have a negative serum or urine pregnancy test at screening, and if heterosexually active, agree to consistently use 2 forms of birth control (at least one of which must be a barrier method) starting at screening and throughout the study period and for 60 days after final study drug administration.Xx_NEWLINE_xXMale subject and a female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (one of which must be a barrier method) starting at screening and continue throughout the study period and for 120 days after the final study drug administration.Xx_NEWLINE_xXif heterosexually active must use two forms of birth controlXx_NEWLINE_xXMale subject and their female spouse/partners who are of childbearing potential must be using highly effective contraception consisting of two forms of birth control (one of which must be a barrier method) starting at Screening and continue throughout the study period and for 90 days after the final study drug administration.Xx_NEWLINE_xXWomen of childbearing potential and male participants must agree to practice adequate means of birth control throughout their participation in the study and for 6 months after their last treatmentXx_NEWLINE_xXIf of childbearing potential, must be practicing double-barrier method of birth control, be willing to avoid pregnancy for the period of study participation and have a negative pregnancy test at screeningXx_NEWLINE_xXInclusion\n\n          1. Has provided written informed consent\n\n          2. Has advanced solid tumors (excluding breast cancer)\n\n          3. Has normal hepatic function, mild, moderate, or severe hepatic impairment\n\n          4. ECOG performance status of ?2\n\n          5. Is able to take medications orally\n\n          6. Has adequate organ function\n\n          7. Women of childbearing potential must have a negative pregnancy test and must agree to\n             adequate birth control if conception is possible. Males must agree to adequate birth\n             control.\n\n        Exclusion\n\n          1. Certain serious illnesses or medical condition(s)\n\n          2. Has had certain other recent treatment e.g. major surgery, anticancer therapy,\n             extended field radiation, received investigational agent, shunt in the liver within\n             the specified time frames prior to study drug administration\n\n          3. Has received TAS-102\n\n          4. Has unresolved toxicity of greater than or equal to CTCAE Grade 2 attributed to any\n             prior therapies\n\n          5. Is a pregnant or lactating femaleXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study up to 4 months after treatment; patients must be willing to undergo testing for HPV-16 prior to becoming pregnantXx_NEWLINE_xXIf fertile male or female of child-bearing potential, agree to consistently use a highly effective method of birth control (including birth control pills, barrier device, or intrauterine device, abstinence or other methods prescribed by a licensed healthcare provider) from the time of consent through 70 days following the last dose of study drugXx_NEWLINE_xXMale and female subjects must agree to use a highly reliable method of birth control for the duration of the study.Xx_NEWLINE_xXWomen of childbearing potential as well as fertile men and their partners must use an effective method of birth controlXx_NEWLINE_xXPregnancy or breastfeeding; women of childbearing potential (WOCBP) must practice acceptable methods of birth control to prevent pregnancy; prior to study enrollment, WOCBP must be advised of the importance of avoiding pregnancy during trial participation and the potential risk factors for an unintentional pregnancy; in addition, men enrolled on this study must be informed of the risks to any sexual partner of childbearing potential and should practice an effective method of birth controlXx_NEWLINE_xXFemale subjects of childbearing potential and males must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatmentXx_NEWLINE_xXPregnant or lactating females are excluded. Women of childbearing age, and their sexual partners, must use an effective contraception program. Males who are having sexual relations with women capable of child bearing must use the barrier birth control while on the study and for 3- months after the last dose of the study drug.Xx_NEWLINE_xXWilling to practice methods of birth control (both males who have partners of childbearing potential and females of childbearing potential) from screening through 3 months after taking the final dose of RTA 408;Xx_NEWLINE_xXAdequate birth control methods for the duration of the studyXx_NEWLINE_xXIf fertile male or female of child-bearing potential, agree to consistently use a highly effective method of birth control (including birth control pills, barrier device, or intrauterine device) from the time of consent through 3 months following the last dose of study drugXx_NEWLINE_xXWomen with child-bearing potential must be willing to practice acceptable methods of birth control during the studyXx_NEWLINE_xXUnwillingness to practice birth controlXx_NEWLINE_xXWoman with child bearing potential must either commit to continued abstinence from heterosexual intercourse or begin TWO acceptable methods of birth control, one highly effective method and one additional effective method AT THE SAME TIMEXx_NEWLINE_xXWomen of childbearing potential must have a negative pregnancy test and must agree to adequate birth control if conception is possible. Males must agree to adequate birth control.Xx_NEWLINE_xXWomen who are pregnant or lactating. Women of child-bearing potential (WOCBP), and fertile men with a WOCBP-partner not using adequate birth control.Xx_NEWLINE_xXNot pregnant or breast feeding; women of childbearing potential and sexually active men must agree to use an accepted and effective method of birth controlXx_NEWLINE_xXWomen must be either of non-childbearing potential or women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study.Xx_NEWLINE_xXPatients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection during the study and for 1 week after the last dose of abiraterone acetateXx_NEWLINE_xXPatients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last study drug administrationXx_NEWLINE_xXWomen who are pregnant or lactating. Women of child-bearing potential (WOCBP) and fertile men with a WOCBP partner, not using adequate birth control.Xx_NEWLINE_xXHighly effective methods of birth control for females & malesXx_NEWLINE_xXFemales of childbearing potential and males must be willing to use an effective method of contraception (hormonal, barrier method of birth control or abstinence) from the time the consent is signed, during the duration of study participation and 4 months after discontinuation of protocol therapyXx_NEWLINE_xXMale patients whose sexual partners are WOCBP not using effective birth controlXx_NEWLINE_xXFemales of child-bearing potential must be willing to practice acceptable methods of birth control. Additionally, females of childbearing potential must have a negative serum pregnancy test within 7 days prior to start of study drugs, throughout treatment period and for 4 months after last dose of study drugs.Xx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for 4 months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screeningXx_NEWLINE_xXPregnant or breast-feeding females are excluded; pregnancy tests must be obtained prior to enrollment for all females of childbearing potential as per institutional standards (at National Institutes of Health [NIH] subjects 9 years and older or those showing pubertal development); males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method; abstinence is an acceptable method of birth controlXx_NEWLINE_xXMale and female patients must agree to use a highly reliable method of birth control.Xx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after receiving treatmentXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on the study and for four months after treatmentXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug by both sexesXx_NEWLINE_xXPatients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this studyXx_NEWLINE_xXWomen of childbearing potential and male participants must agree to use a medically effective means of birth control, such as condom/diaphragm and spermicidal foam, intrauterine device (IUD), or prescription birth control pills, throughout their participation in the treatment phase of the studyXx_NEWLINE_xXPatients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 1 week after last dose of abiraterone acetateXx_NEWLINE_xXSexually active fertile men not using effective birth control if their partners are WOCBPXx_NEWLINE_xXPregnant and/or lactating women will be excluded; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatmentXx_NEWLINE_xXWomen who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control; double barrier contraceptives must be used through the trial by both sexes; oral, implantable, or injectable contraceptives may be affected by cytochrome P450 interactions, and are therefore not considered effective for this studyXx_NEWLINE_xXWomen of childbearing potential not using a highly effective method of birth control during the trial until one year after the last dose.Xx_NEWLINE_xXWomen of childbearing potential with a positive serum pregnancy test performed within 7 days prior to the start of treatment; women and men of childbearing potential that do not agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; men who do not agree to use adequate birth control for at least three months after the last administration of sorafenibXx_NEWLINE_xXMen and woman of reproductive potential, unwilling to practice a highly effective method of birth control for the duration of the study and continuing for 2 weeks (for women) and 12 weeks (for men) after receiving the last dose of study drug.Xx_NEWLINE_xXWomen with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 4 weeks after the last dose of study medication.Xx_NEWLINE_xXMen with reproductive potential must be willing to practice acceptable methods of birth control during the study and for up to 16 weeks after the last dose of study medication.Xx_NEWLINE_xXPatients who are potentially fertile and sexually active must be willing to utilize effective birth controlXx_NEWLINE_xXPregnant or lactating females are excluded. Women of childbearing age, and their sexual partners, must use an effective contraception program. Males who are having sexual relations with women capable of child bearing must use birth control while on the study and for 3-months after the last dose of the study drug.Xx_NEWLINE_xXFemales of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 4 weeks after treatment discontinuation.Xx_NEWLINE_xXCurrent use of hormone-containing forms of birth control such as implants (i.e. Norplants, or injectables ( i.e. depo-provera)Xx_NEWLINE_xXInability or refusal to practice effective contraception during therapy or the presence of pregnancy or active breastfeeding (men and women of childbearing potential must use an effective method of birth control or abstinence during treatment and for four months after completion of treatment)Xx_NEWLINE_xXSubjects of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this study (cohort 1)Xx_NEWLINE_xXSubjects of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while they are being treated on this studyXx_NEWLINE_xXAdequate birth controlXx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; if barrier contraceptives are being used, these must be continued throughout the trial by both sexes; hormonal contraceptives are not acceptable as a sole method of contraception (women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of EVEROLIMUS)Xx_NEWLINE_xXThere is no available information, as yet, regarding human fetal or teratogenic toxicities; pregnancy tests with a negative result must be obtained in girls who are postmenarchal within 10 days before start of treatment; women of childbearing potential and men must agree to use adequate contraception (barrier method of birth control) prior to study entry and for the duration of study participation; men and women should use adequate birth control for at least three months after the last administration of study treatmentXx_NEWLINE_xXMen capable of producing offspring and not surgically sterile must practice abstinence or use a barrier method of birth control.Xx_NEWLINE_xXFemale patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods; adequate contraception must be used throughout the trial and for 8 weeks after the last dose of study drug, by both sexes (women of childbearing potential [WOCBP] must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001)Xx_NEWLINE_xXWomen with potential to have children must be willing to practice acceptable methods of birth control during the study;Xx_NEWLINE_xXUse of acceptable birth controlXx_NEWLINE_xXSexually active women of childbearing potential must use effective birth control during the trial and for at least two months following the trial, and sexually active men must be willing to avoid fathering a new child while receiving therapyXx_NEWLINE_xXFemale patients of childbearing age not on effective birth controlXx_NEWLINE_xXFemales and males must be willing to use an approved form of birth control while on this study and for 2 weeks after completion.Xx_NEWLINE_xXPatients of reproductive age must agree to use a medically accepted form of birth control while on the study.Xx_NEWLINE_xXWomen who are pregnant or breast feeding or women of childbearing potential (WOCBP) not using 2 reliable forms of birth controlXx_NEWLINE_xXChildbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (IUD, birth control pills, or barrier device) during and for 3 months after completion of trial therapy.Xx_NEWLINE_xXWomen and men agree to use protocol specific birth control measuresXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test; patients of childbearing potential must agree to use an effective birth control method; female patients who are lactating must agree to stop breast-feedingXx_NEWLINE_xXAny of the following:\r\n* Pregnant persons\r\n* Nursing persons\r\n* Persons of childbearing potential who are unwilling to employ adequate contraception; Note: persons of childbearing potential and persons able to father a child who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; subjects must agree to not donate sperm during and after the study; for persons of childbearing potential, these restrictions apply for 1 month after the last dose of study drug; for persons able to father a child, these restrictions apply for 3 months after the last dose of study drugXx_NEWLINE_xXTo avoid risk of drug exposure through the ejaculate (even men with vasectomies), subjects must use a condom during sexual activity while on study drug and for 3 months following the last dose of study drug; if the subject is engaged in sexual activity with a woman of childbearing potential, a condom is required along with another effective contraceptive method consistent with local regulations regarding the use of birth control methods for subjects participating in clinical studies and their partners; donation of sperm is not allowed while on study drug and for 3 months following the last dose of study drugXx_NEWLINE_xXIf female patient with reproductive capacity: on effective means of barrier birth control during the entire duration of the treatmentXx_NEWLINE_xXPregnant women are ineligible, as treatment involves unforeseeable risks to the embryo or fetus; female patients with reproductive capacity are required to use effective means of birth control during the entire duration of the treatmentXx_NEWLINE_xXPatients of reproductive potential who are not employing an effective method of birth control; male patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy, whichever is the longer time periodXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for 3 months after the last dose of ibrutinib and 6 month after the last dose of nivolumab; for males, these restrictions apply for 3 month after the last dose of study drugsXx_NEWLINE_xXPatients must be willing to practice birth control during and for four months following treatmentXx_NEWLINE_xXA man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control e.g., either condom with spermicidals or partner with occlusive cap with spermicidals and all men must also not donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXIf heterosexually active must use two forms of birth control* (at least one of which must be a barrier method) starting at screening and throughout the study period and for 28 days after the final study drug administration.Xx_NEWLINE_xXMale subject and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of two forms of birth control* (one of which must be a barrier method) starting at screening and continue throughout the study period and for 90 days after the final study drug administration.Xx_NEWLINE_xXMale subject must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration. *Acceptable forms of birth control include:Xx_NEWLINE_xXMen and women of childbearing potential must agree to use adequate contraception (double barrier birth control) for the duration of study therapyXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active with a woman of childbearing potential must be practicing a highly effective method of birth control during and after the study (12 months for women and 3 months for men), consistent with local regulations regarding the use of birth control methods for subjects participating in this clinical studyXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXPatients of both genders must be willing to practice birth control from the time of enrollment on this study and for up to four months after treatmentXx_NEWLINE_xXWomen and men of reproductive potential must agree to use an effective means of birth control during the study and for 3 months after receiving study drugXx_NEWLINE_xXPregnant or breast feeding; women and men of reproductive potential must agree to use an effective means of birth control during the study and for 3 months after receiving study drugXx_NEWLINE_xXFemales or males whose partners are women of childbearing potential must agree to use a reliable method of birth control prior to drug initiation and for the duration of their study participationXx_NEWLINE_xXWomen of child-bearing potential must agree to utilize a form of birth control or agree to undergo sexual abstinence during radiation therapyXx_NEWLINE_xXPregnant women or women who are breast feeding or of child bearing potential not using a highly effective method of birth control for at least one month prior to enrollment\r\n* Patients will be considered to be of childbearing potential unless surgical sterilized by hysterectomy or bilateral tubal ligation/salpingectomy, or post-menopausal for at least two years; women of childbearing potential who are sexually active and not using a highly effective method of birth control before the trial for at least one month, during the trial, and for at least three months after the end of active therapy are not allowed to participate in the trial; a highly effective method of birth control is defined as one which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, intrauterine devices (IUDs), sexual abstinence or vasectomized partnerXx_NEWLINE_xXSexually active males not committing to birth control during the course of the study (except if their partner is not of childbearing potential)Xx_NEWLINE_xXA male patient and his female partner who is of childbearing potential must use 2 acceptable methods of birth control (one of which must include a condom as a barrier method of contraception) starting at screening and continuing throughout the study period and for 3 months after final study drug administrationXx_NEWLINE_xXFemale patients who are pregnant or lactating, or are of childbearing potential (FCBP, defined as all women physiologically capable of becoming pregnant) and not practicing an effective method of contraception/birth control\r\n* FCBP must have a current negative serum pregnancy test prior to transplant per institutional practiceXx_NEWLINE_xXMale and female subjects of reproductive potential who agree to use both a highly effective method of birth control and a barrier method during the period of therapy and for 90 days after the last dose of drug.Xx_NEWLINE_xXWomen of childbearing potential are will to agree to use 1 of the study defined effective methods of birth control from the time of study entry to 60 days after the final study drug administrationXx_NEWLINE_xXMale patients must use highly effective contraception methods consisting of 2 forms of birth control (at least 1 of which must be a barrier method) starting at screening and continuing throughout the study period and for 60 days after the final study drug administration.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative serum pregnancy test at screening, and must agree to use a highly effective birth control method from the time of the first dose of study drug through 45 days after the last dose of study drug.Xx_NEWLINE_xXWomen of childbearing potential and their male partners must agree to use TWO effective forms of birth control (abstinence is not an allowed method) prior to study entry and for the duration of study participation, and for two months following the last dose of study medications; effective birth control methods are: copper IUD [intrauterine device], diaphragm/cervical cap/shield, spermicide, contraceptive sponge, condoms; women of childbearing potential must have a negative pregnancy test within seven days before starting study medications; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediatelyXx_NEWLINE_xXSubject and female partner who is of childbearing potential must continue to use 2 forms of birth control, of which 1 must be highly effective and 1 must be a barrier method throughout the study and for 3 months after final enzalutamide administration.Xx_NEWLINE_xXFemale patients of childbearing potential must have a negative pregnancy test before the first dose of talazoparib and must agree to use a highly effective birth control method from the time of the first dose of talazoparib through 45 days after the last dose.Xx_NEWLINE_xXAgrees to use a condom (even men with vasectomies) and another effective method of birth control if he is having sex with a woman of childbearing potential or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug; must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drugXx_NEWLINE_xXWomen of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials; men must agree to not donate sperm during and after the study; for females, these restrictions apply for 1 month after the last dose of study drug; for males, these restrictions apply for 3 months after the last dose of study drugXx_NEWLINE_xXWomen who are not practicing an effective form of birth control (condoms, diaphragm, birth control pill, intrauterine device [IUD]) or currently pregnantXx_NEWLINE_xXPregnant or lactating women, childbearing age women who are not on birth control; negative pregnancy test for women of childbearing potential, as defined by intact uterus and ovaries, and a history of menses within the last 12 months; pregnancy test to be performed no greater than 14 days prior to consent in study; in cases of women with elevated b-HCG, these candidates will be eligible to participate so long as the level of b-HCG is not consistent with pregnancy; women of childbearing potential need to be on or use contraception, or be abstinent during the study period; their male partners must also use contraception (condom) or maintain abstinence; birth controls specifications: women who are able to become pregnant must use birth control during the study and for 30 days after the last anamorelin dose; acceptable forms of birth control include barrier methods (such as condom or diaphragm) with spermicideXx_NEWLINE_xXMale and females of child bearing potential must use acceptable methods of birth control which include oral contraceptives, spermicide with either a condom, diaphragm or cervical cap, use of an intrauterine device (IUD) or abstinence; (1) female patients must have a negative pregnancy test at screening; (2) female patients of childbearing potential must agree to use an acceptable method of birth control (excluding hormonal birth control methods) for 72 hours prior to admission and to continue its use during the study and for at least 30 days after the final dose; (3) male patients must agree to use an acceptable form of birth control from study day 1 through at least 30 days after the final doseXx_NEWLINE_xXEither post-menopausal, surgically sterilized, or willing to use an acceptable method of birth control during study treatment and for 3 months afterwardsXx_NEWLINE_xXMale and female patients who are fertile who do not agree to use an effective barrier methods of birth control (i.e. abstinence) to avoid pregnancy while receiving study treatmentXx_NEWLINE_xXFor women of childbearing potential: unwillingness to use an effective method of birth control (e.g., abstinence, oral contraceptive) while in this studyXx_NEWLINE_xXPregnant or able to become pregnant and unwilling to use two forms of birth control during the study periodXx_NEWLINE_xXWomen of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth controlXx_NEWLINE_xXPatients must agree to use an effective birth control methodXx_NEWLINE_xXFor sexually active females, patient agrees to use acceptable method of birth controlXx_NEWLINE_xXIf a woman of childbearing potential, must have a negative serum pregnancy test upon entry into this study and must be willing to use highly effective birth control upon enrollment, during the treatment period and for 6 months following the last dose of investigational drug or cytarabine, whichever is later. A woman is considered of childbearing potential following menarche and until becoming postmenopausal (no menstrual period for a minimum of 12 months);Xx_NEWLINE_xXIf male, must be surgically sterile or willing to use highly effective birth control upon enrollment, during the treatment period, and for 6 months following the last dose of investigational drug or cytarabine, whichever is later.Xx_NEWLINE_xXSexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the studyXx_NEWLINE_xXAcceptable birth control.Xx_NEWLINE_xXParticipant must be willing to use two effective forms of birth control during protocol therapy; men and women must continue using two effective forms of birth control for 6 months following treatmentXx_NEWLINE_xXMale and female subjects of child-bearing potential must agree to use medically acceptable methods of birth control throughout the study and for thirty (30) days after the last dose of study medication.Xx_NEWLINE_xXMen who could father a child must agree to use at least one form of birth control during or continued abstinence from heterosexual intercourse if receiving topical treatment during the study, and for 2 weeks after stopping topical treatmentXx_NEWLINE_xXNegative pregnancy test for women of childbearing potential, as defined by intact uterus and ovaries, and a history of menses within the last 12 months; pregnancy test to be performed no greater than 14 days prior to consent in study; in cases of women with elevated beta human chorionic gonadotropin (b-HCG), these candidates will be eligible to participate so long as the level of b-HCG is not consistent with pregnancy; women of childbearing potential need to be on or use contraception, or be abstinent during the study period; their male partners must also use contraception (condom) or maintain abstinence; birth controls specifications; women who are able to become pregnant must use birth control during the study and for 30 days after the last ginseng/placebo dose; acceptable forms of birth control include barrier methods (such as condom or diaphragm) with spermicideXx_NEWLINE_xXFemales of childbearing potential must use a highly effective method of birth control for at least 28 days before starting study, during participation and at least 112 days following last dose of sotaterceptXx_NEWLINE_xXAgree to utilize medically accepted methods of birth control during study participation and for 90 days following the last treatment with study drug if a female subject is of childbearing potential or if a male subject has an opposite sex partner of child bearing potential.Xx_NEWLINE_xXWomen of reproductive capability will be enrolled, but each woman needs to discuss with the study team the method of birth control used and if the method is a reliable and effective method for her; if a woman becomes pregnant during the course of active study participation, she must agree prior to enrolling in the study that she will report the pregnancy to the study team; with a confirmed pregnancy, the subject will no longer receive the assigned treatment, but will continue to be followed per protocolXx_NEWLINE_xXPatients who have partners of childbearing potential must be willing to use a method of birth control with adequate barrier protection during the study and for 1 week after the last dose of ranolazineXx_NEWLINE_xXSexually active female patients of reproductive potential are not eligible unless they agree to use an effective contraceptive method during study and for 2 months after stopping the study drug; abstinence is an acceptable method of birth controlXx_NEWLINE_xXWomen of childbearing potential (FCBP) must have a negative urine pregnancy test within 7 days prior to randomization enrollment; female participants enrolled in the treatment arm are advised to not become pregnant during study participation; all women of childbearing potential must agree to either commit to continued abstinence from heterosexual intercourse or to use a reliable birth control method during heterosexual intercourse (oral contraceptive pills, intrauterine device, Nexplanon, DepoProvera, or bilateral tubal ligation, etc., or another acceptable method as determined by the investigator) during the entire period of the trial (5 years or more), and must not intend to become pregnant during study participation and for 3 months after treatment is discontinued if the participant is enrolled in the treatment arm; female participants, if engaging in heterosexual intercourse, must be willing to comply with an acceptable birth control regimen as determined by the investigatorXx_NEWLINE_xXIf currently menstruating, subjects must use a reliable method of birth controlXx_NEWLINE_xXFemales of childbearing potential must have a negative pregnancy test. Patients of childbearing potential must agree to use an effective birth control method. Female patients who are lactating must agree to stop breast-feeding.Xx_NEWLINE_xXPremenopausal women taking non hormonal intra-uterine device (IUD) birth control method will be eligible, if they have been on the same IUD for at least 3 months prior to enrollment and plan to continue using the same method throughout the studyXx_NEWLINE_xXPregnant, or had given birth, or nursed at any time during the last 12 monthsXx_NEWLINE_xXWomen of childbearing potential (WOCBP) must practice 2 effective methods of birth control during the course of the study; male patients who are partners of WOCBP should also practice an effective method of contraception; effective methods of birth control include diaphragm or condoms with spermicidal foam or jelly, birth control pills (BCPs), injections or patches, intra-uterine devices (IUDs) and surgical sterilizationXx_NEWLINE_xXWomen and men must continue birth control for the duration of the trial and >= 3 months after the last dose of study drugXx_NEWLINE_xXFemale patients of childbearing potential must agree to use an acceptable method of birth control from the signing of informed consent form and to continue its use during the study and for at least 90 days after the final doseXx_NEWLINE_xXMale patients must agree to use an acceptable form of birth control from study day 1 through at least 90 days after the final doseXx_NEWLINE_xXBreast surgeons may recommend that this patient population should not take any oral contraceptives or hormone eluting intrauterine devices (IUDs); sexually active heterosexual women must agree to use an effective form of birth control for the duration of study participation; women who are NOT having 1) a hysterectomy, 2) fallopian tubes removed and/or 3) ovaries removed at the time of their breast surgery will also be required to use an effective form of birth control for 56 days following the last dose of study medication\r\n* The following women are not considered able to bear children and therefore are eligible to participate without the use of concurrent birth control:\r\n** Female with hysterectomy with intact functioning ovaries\r\n** Female with fallopian tubes cut, tied, sealed, or removed\r\n** Female with sterilization implant (e.g. Adiana, Essure) place > 3 months prior to beginning study drug\r\n* One of the following methods of birth control must be used by sexually active women of childbearing potential for the duration of study participation and for 56 days following the last dose of study medication:\r\n** Combined oral contraceptive pill in continuous use for > 90 days prior to study entry\r\n** Vaginal ring (e.g.NuvaRing) in continuous use for > 90 days prior to study entry\r\n** Skin patch (e.g. Ortho Evra) in continuous use for > 90 days prior to study entry\r\n** Injection (e.g. Depo-Proveera, Noristerat) in continuous use prior to study entry\r\n** IUD\r\n** Diaphragm, cervical cap, or cervical shield with spermicide\r\n** Contraceptive sponge (e.g. Today Sponge)\r\n** Condom (male or female type) plus spermicide\r\n** Male partner who has had a vasectomy\r\n* Women who indicate that they are abstinent from heterosexual encounters for the duration of study participation and for the 56 days following the last dose of study medication will not be required to use birth controlXx_NEWLINE_xXIf female, agreement to use birth control (any form) to avoid pregnancy during study proceduresXx_NEWLINE_xXMust agree to use effective consistent contraception. Hormone-based birth control (pills, patches, or shots) is allowed. Hormone replacement therapy is not allowed for postmenopausal participants.Xx_NEWLINE_xXIf male, must be surgically sterile or willing to practice two effective methods of birth controlXx_NEWLINE_xXSexually active females of childbearing potential and males with partners of child-bearing potential must agree to use adequate birth control during study treatmentXx_NEWLINE_xXWilling to use adequate contraception (barrier method, abstinence, subject has had a vasectomy or partner is using effective birth control or is postmenopausal) for the duration of study participationXx_NEWLINE_xXParticipants will be required to use a medically-approved method of birth control or abstinence if their sexual partner is of child-bearing potentialXx_NEWLINE_xXCONTROL GROUPXx_NEWLINE_xXParticipants of reproductive potential agree to remain abstinent, or use a medically accepted method of birth controlXx_NEWLINE_xXWomen of childbearing potential must agree to use a medically acceptable form of birth control (medically accepted methods: birth control pills, condoms and spermicidal lubricants, intrauterine device, and diaphragm) during their participation in the studyXx_NEWLINE_xXWomen who are pregnant or breast feeding. Adults of reproductive potential not willing to employ two forms of birth control.Xx_NEWLINE_xXMale and female subjects must agree to use a highly reliable method of birth control (expected failure rate less than 5% per year) from the screening visit through 28 days after the last dose of study drug. Women of childbearing potential must have a negative pregnancy test at screening.Xx_NEWLINE_xXMale patients must be willing to practice birth control (including abstinence) during and for 4 months after treatment. Female patients must be willing to practice birth control (including abstinence) during treatment and for 4 months after gene modified cells are no longer detected in body.Xx_NEWLINE_xXMale and female subjects of childbearing potential must agree to use a highly reliable method of birth control (expected failure rate < 1% per year) from the Screening Visit through 28 days after the last dose of study drug. Women of childbearing potential must have a negative pregnancy test at screening.Xx_NEWLINE_xXAre pregnant, breastfeeding, or unwilling to practice an acceptable form of birth control during the study.Xx_NEWLINE_xXFemale or male participant who is not of reproductive potential, or, if of reproductive potential, agrees to true abstinence or to use (or have their partner use) 2 acceptable methods of birth control from the time of consent through 90 days after the last dose of study drugXx_NEWLINE_xXFertile subjects must use adequate contraception (abstinence, barrier methods, or birth control pills) prior to study entry and for the duration of study participationXx_NEWLINE_xXAll patients of childbearing age must use an acceptable form of birth controlXx_NEWLINE_xXAgree to use an acceptable form of birth control for a period of 7 days after the Cu-64-TP3805 injectionXx_NEWLINE_xXNot currently on estrogen medication for birth control, menopause, or other reasonXx_NEWLINE_xXWomen of child-bearing potential must be willing to practice an effective method of birth control while on studyXx_NEWLINE_xXAll patients of childbearing and child-creating age must be using an acceptable form of birth controlXx_NEWLINE_xXWillingness to use birth control while on studyXx_NEWLINE_xXCONTROL GROUPXx_NEWLINE_xXAll patients of childbearing and child-creating age must be using an acceptable form of birth controlXx_NEWLINE_xXBirth weight below five pounds, premature birth prior to 36 weeks of gestation, or ischemic episode at birthXx_NEWLINE_xXPatients who have partners of childbearing potential who are not willing to use a method of birth control with adequate barrier protection as determined to be acceptable by the principal investigator and sponsor during the study and for 13 weeks after last study drug administrationXx_NEWLINE_xXFor women of childbearing potential, agreement to use an effective form of contraception (patient and/or partner, e.g., surgical sterilization, a reliable barrier method, birth control pills, or contraceptive hormone implants) and to continue its use for the duration of the study treatment, and for a minimum of 6 months following trastuzumab and/or pertuzumab administrationXx_NEWLINE_xXCurrently using two forms of effective birth control (one of which is a barrier method) for the duration of the study for both males and females of childbearing potential. Effective methods of birth control include hormonal contraception (i.e., birth control pills, injected hormones, vaginal ring), intrauterine device, or barrier methods with spermicide (i.e., diaphragm with spermicide, condom with spermicide), orXx_NEWLINE_xXSubjects who are of reproductive potential who refuse to use effective methods of birth control during the course of participation of the study and within 5 month for women and 7 months for men of the last dose of investigational agent are ineligible to participate in the study.Xx_NEWLINE_xXSubjects of both genders of child-bearing potential who are not willing to practice birth control from the time of consent through 6 months after the completion of KITE-718Xx_NEWLINE_xXPatients must not be pregnant; all premenopausal patients will undergo pregnancy testing; men will agree to not father a child while on protocol treatment; men and women will practice effective birth control while receiving protocol treatmentXx_NEWLINE_xXWomen of childbearing potential not practicing adequate forms of birth controlXx_NEWLINE_xXFemale of child bearing potential (FCBP) and non-vasectomized male agree to practice appropriate methods of birth controlXx_NEWLINE_xXAdequate birth controlXx_NEWLINE_xXPregnancy, lactation or inability to use medically acceptable birth control if of childbearing potentialXx_NEWLINE_xXMale participants: Agree to use a reliable method of birth control and to not donate sperm during the study and for at least 12 weeks following last dose of study drug or country requirements, whichever is longer.Xx_NEWLINE_xXSexually active and not willing/able to use medically acceptable forms of contraception (hormonal or barrier method of birth control, abstinence) upon entering the study and for 60 days after injection of LUM015.Xx_NEWLINE_xXFemale patients of childbearing potential and male patients with partners of childbearing potential must continue to use an effective method of birth control as well as their partners.Xx_NEWLINE_xXWomen of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) starting the day entering the study, and for 60 days after injection of the imaging agent.Xx_NEWLINE_xXFemale patients of child bearing potential and non-vasectomized male patients agree to practice appropriate methods of birth controlXx_NEWLINE_xXMales, and female patients who are biologically capable of having children, must agree to use a medically acceptable method of birth control.Xx_NEWLINE_xX